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 Abstract 
The client, LifeLabs, invests millions of dollars annually in capital equipment purchases, with the 
majority of this spend being directed at replacement, upgrades and introductions of new test 
instruments. Despite the strategic nature of these decisions, the current decision making process 
employed by LifeLabs does not include evaluation of external environmental factors that may 
influence long-run profitability and risk. LifeLabs has commissioned this study to deliver an 
external analysis of the medical diagnostic laboratory industry in British Columbia, further 
requesting that the study focus on delivering recommendations for the industry segments of 
allergy, autoimmune and coagulation. The results of the analysis conducted herein are as follows: 
 
To maximize future allergy segment attractiveness, it is recommended that med-lab providers 
collaborate with allergy specialists to install point of care technology (POCT) allergen testing 
capability at locations close to the specialists’ places of practice. 
 
To maximise future autoimmune segment attractiveness, it is recommended that med-lab 
providers educate family physicians and rheumatology specialists regarding the benefits and best 
uses of complementary test methods (such as IFA and Bio-Plex), as well as how to interpret 
results from those methods. 
 
To maximise future coagulation segment attractiveness, it is recommended that med-lab providers 
collaborate with regional health authorities to install POCT coagulation testing (Prothrombin 
Time (PT) / International Normalized Ratio (INR)) capability at locations close to or within 
community acute care clinics, as well as nominated patient service centres, and throughout the 
long term care facility network. 
 
Although it was the clients’ explicit request not to tackle internal analysis as part of this study, it 
is also recommended that a follow-up internal analysis, and subsequent scenario analysis, be 
conducted to assure that the unique competitive advantages of the client firm are considered as 
part of the strategy formulation process. 
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 Glossary 
Inpatient A patient that is hospitalized for a period of 24 hours or more. 
Outpatient A patient that is treated without hospitalization. 
Allergy  An immune system hyper-sensitivity that results in immune system responses to 
otherwise harmless substances.  
Autoimmune 
Diseases 
Diseases related to the immune system attacking the host’s body, e.g. rheumatoid 
arthritis 
Coagulation 
Related Diseases 
Conditions that interfere with the normal clotting of blood, including excessive 
bleeding (haemorrhaging) or clotting (thrombosis), e.g. Stroke. 
Screening Tests Tests that are intended to detect the presence, or predisposition to, a disease in an 
individual.  
Confirmation 
Tests 
Tests that are intended to confirm the presence, or predisposition to, a disease in an 
individual, as well as to provide a more specific classification of the disease. 
Sensitivity A measure of the proportion of actual positives which are correctly identified as such 
(e.g. the percentage of sick people who are correctly identified as having the 
condition). 
Specificity A measure of the proportion of actual negatives which are correctly identified as such 
(e.g. the percentage of healthy people who are correctly identified as not having the 
condition). 
PT  Prothrombin Time (PT) is a test used to evaluate the ability of blood to clot properly 
by evaluating the function of coagulation factors, and has numerous applications 
including pre-surgery screening of patients for any previously undetected bleeding 
disorders.  
INR International Normalized Ratio (INR) is a test used to monitor the effectiveness of 
blood thinning drugs such as warfarin (Coumadin). 
CBC Complete Blood Counts (CBC’s) are amongst the most commonly performed tests in 
medicine. Abnormally high or low counts may indicate the presence of many forms of 
disease, hence blood counts can provide an overview of a patient's general health 
status. 
ANA Antinuclear antibody (ANA) testing is used in the detection of lupus and mixed 
connective tissues disease. 
 x 
 POCT Point of care technology. Small scale test equipment capable of delivering fast 
convenient test results. 
BCMA British Columbia Medical Association 
CPSBC College of Physicians and Surgeons of British Columbia 
BCALP British Columbia Association of Laboratory Physicians 
DAP Diagnostic Accreditation Program (Administered by the CPSBC) 
TAT Turn-around-time for a test; a measure of service delivery. 
 xi 
 1: Introduction 
1.1 Client Overview 
LifeLabs is a medical diagnostic laboratory (med-lab) services company that annually provides 
more than 50 million laboratory tests to over 10 million patients and nearly 20,000 physicians 
across British Columbia, Ontario and Quebec. LifeLabs services the diagnostic needs of 
outpatients (patients that are not hospitalized) by providing province-wide access to a full range 
of laboratory testing and information services. 
 
LifeLabs is privately owned by Borealis Infrastructure. Borealis acts as the infrastructure 
investment arm of Ontario Municipal Employees Retirement System (OMERS), a Canadian 
pension plan with approximately C$50 billion in net investment assets (Borealis, 2011). LifeLabs 
operates in a multi-goal environment with ultimate goals of long-run profitability and social 
responsibility.  The latter is defined as the intent to contribute to the improvement of healthcare 
delivery in any market that it serves.  
 
1.2 The Problem  
LifeLabs invests millions of dollars annually in capital equipment purchases, with the majority of 
this spend being directed at replacement, upgrades or introductions of new test instruments. 
Equipment selection decisions that underlie investments in test instruments are strategic in nature 
as the investments involve large sums of money, are long lived and highly specific in nature, and 
affect the type of services that can be offered to clients. Despite the strategic nature of these 
decisions, the current decision making process employed by LifeLabs does not include evaluation 
of external and environmental factors that may influence long-run profitability and risk. 
      
1.3 The Approach  
LifeLabs has acknowledged this gap in the understanding of external factors, and has requested 
this study to deliver an external analysis of the medical diagnostic laboratory industry in British 
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 Columbia (BC). To exploit the earliest possible opportunity for integration of this analysis into its 
test instrument investment decision making process, LifeLabs has requested that this study focus 
on the industry segments of allergy, autoimmune and coagulation. Instruments in each of these 
three areas are approaching the limits of their usable life.    
  
To address the client’s needs, Chapter Two will describe the medical diagnostic laboratory 
industry in BC, including: the services and customers, industry boundaries, industry segments, 
strategic groups, industry supply chain and market structure. Chapter Three will then analyse the 
external forces (specific to the segments of allergy, autoimmune and coagulation) that affect 
industry profitability now and in the future, using various tools including a Porter’s Five Forces 
framework. Finally, Chapter Four will assess the implications of the findings of the external 
forces analysis for the client’s strategy, and make recommendations regarding threat mitigation 
and opportunity exploitation.  
 2
 2: Description of the Medical Diagnostic Laboratory Industry 
The following section provides a detailed description of the medial diagnostic laboratory industry 
in BC in terms of services and customers, segmentation, strategic groups, industry boundaries, 
market structure, and supply chain.     
2.1 Overview of Services and Customers 
The medical diagnostic laboratory (med-lab) industry provides an extensive menu of tests that 
physicians and surgeons can order as a complement to their clinical investigation (direct 
consultation with patients), to assist in the diagnosis and treatment of disease. Med-lab testing 
results are a key input in about 70 % of decisions that physicians make (D. King, 2010). 
 
Patients of physicians and surgeons are the main customer group of the (med-lab) industry in BC. 
“Patients” include inpatients, defined as patients who are hospitalized, and outpatients, defined as 
patients who are not hospitalized but who visit a hospital, clinic, or associated facility, or are 
visited by a health service provider, for diagnosis and treatment (Wikipedia, 2011).  In addition to 
services offered at community clinics and doctor’s offices, outpatient med-lab services also 
include mobile collection from patient’s homes, long term care facilities, assisted living facilities, 
and remote communities. Although patients are the end customer, they do not choose or directly 
pay for most tests. Physicians choose the appropriate tests and the government pays for them via 
the provincial medical insurance plan (MSP).   
 
In addition to patients, the industry also services the following customers: government 
organizations such as BC Cancer; pharmaceutical companies (enabling clinical trials); and 
corporate clients (enabling executive health programs, screening for illegal drugs, etc.).  
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 2.2 Industry Segmentation 
Industry segmentation is important in a number of ways. It identifies distinct groups of customers, 
and by extension, opportunities to effectively and efficiently service their distinct needs. It also 
provides insight into strategic groups operating in the industry and provides an opportunity to 
identify a mode of segmentation that is the most relevant to the client’s issue - capital investment 
in test instruments.  
  
The following discussion will present four different ways to segment the med-lab industry in BC: 
segmentation by customer type, by geography, by funding type, and by medical discipline.  
2.2.1 Segmentation by Customer and Product Type 
The first and largest customer segment, representing more than 90% of the market, is that of 
patients (LifeLabs, 2011). Further segmentation of this group, into inpatients and out-patients, 
reveals a distinct focus for each sub-group. Services provided to inpatients who are hospitalized 
fall into the acute care category. These acute care tests support emergency medicine and 
surgeries and are provided exclusively by public hospitals, which specialize in services for 
inpatients. Services provided to outpatients include the categories of screening, e.g. cancers, trace 
metals; chronic disease management, e.g. diabetes, kidney disease, heart and stroke; and 
infectious disease, e.g. hepatitis, HIV. Although outpatient services are provided by both public 
hospitals and private community labs, the later group delivers the vast majority, approximately 
two-thirds of services to outpatients in BC (Medical Services Commission, 2009). 
  
Services provided to the second customer group, government or private research organizations 
such as pharmaceutical companies, fall into the category of studies, and include: clinical trials, 
e.g. drug trials; and population studies, e.g. aboriginal health studies. 
 
Services provided to the final customer group, corporate clients, fall into the category of 
screening, and include: executive health testing, generally composed of a panel (group) of tests; 
screening for occupational exposure, e.g. heavy metals; and screening for drugs of abuse, e.g. 
cocaine, methamphetamine.   
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 2.2.2 Segmentation by Geography 
BC can be divided into five regions: Vancouver Coastal (Lower Mainland), Fraser Valley, 
Vancouver Island, Interior BC and Northern BC, consistent with the organization of public health 
authorities as depicted in Appendix A. Each of these regions has a number of hub hospitals and a 
network of outpatient services.  
 
 
Service providers focus their operations geography. Specifically, BC Biomedical provides access 
to lab services primarily in the Fraser Valley and Vancouver Coastal, Valley Medical Labs 
provides access to lab services exclusively in the BC Interior, and LifeLabs provides lab services 
across BC. However, LifeLabs has a much smaller presence in the Fraser Valley and the BC 
Interior than it does elsewhere. Public hospitals are managed by regional public health authorities 
and thus inherently geographically focused. 
 
Table 2.2  Industry Segmentation Matrix – LifeLabs Participation 
Diagnostic Services
Vancouver Fraser Valley
Vancouver 
Island Northern Interior
Studies - includes clinical trials, 
population studies (e.g. aboriginal 
health), BC Cancer or BC Centre of 
Disease Control (CDC) funded studies
Predictive Medicine (Genomics) - 
currently negligible
Screening - includes preventative 
health, cancer screening, drugs of 
abuse, trace metals, executive health
Chronic Disease Management - 
includes monitoring of therapeutic drugs 
levels e.g. stroke medication / blood 
thinners
Infectious Disease - includes screening 
and confirmation (e.g. Hepatitis B), and 
may include strain identification.
Acute Care - includes urgent tests (e.g. 
blood cultures) that need to be carried 
our rapidly to prevent possible death 
from illness.
Customers
British Columbia Residents
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 2.2.3 Segmentation by Funding Type 
Med-lab testing is funded using a number of mechanisms, including block and global public 
funding, lump sum annual funding allocated to hospitals by the BC Ministry of Health Services; 
BC medical services plan (MSP); out-of-province funding, covered by another province’s 
provincial medical plan; federal government funding, e.g. immigration, armed forces, veteran 
affairs; private insurance; and patient pay.  
 
For simplicity, the market will be segmented based on the categories of public funding (global), 
public funding (fee schedule, assumed to include the middle three categories discussed above), 
and private funding. Public funding (global) is only available to public hospital med-labs, while 
private funding is only available to private med-labs. Public funding (fee schedule) is available to 
both public and private med-labs.       
2.2.4 Segmentation by Medical Discipline 
Med-lab testing can also be segmented by medical discipline, according to the specialities of the 
medical and scientific doctors who are employed by med-labs to assure test integrity and interpret 
results. These disciplines included clinical chemistry, hematology, microbiology, molecular 
diagnostics, histology, and cytology. 
 
Even finer segmentation, by medical sub-discipline (or sub-specialty) is of particular relevance to 
the client, as it most closely corresponds to test instrument product groupings. The medical 
disciplines of chemistry and hematology will thus be described in greater detail to provide the 
sub-speciality (allergy, autoimmune, and coagulation) level descriptions necessary to support the 
sub-specialty level analysis that takes place in Chapter 3.  
 
The following section provides an overview of each discipline: 
2.2.4.1 Chemistry 
Chemistry is a branch of clinical medicine concerned with the testing of bodily fluids. The 
discipline originated in the late 19th century with the use of simple chemical tests for various 
components of blood and urine. More sophisticated techniques were subsequently added and 
clinical chemistry now has a very broad array of tests, which can be grouped into the sub-
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 specialties of: routine chemistry; endocrinology, the study of hormones; immunology, the study 
of the immune system and antibodies; and pharmacology and toxicology, the study of drugs. 
 
Most tests (assays) are carried out on serum or plasma. Serum is the yellow watery part of blood 
that is left after blood has been allowed to clot and all blood cells have been removed. This is 
most easily done by centrifugation which packs the denser blood cells and platelets to the bottom 
of the centrifuge tube, leaving the liquid serum fraction resting above the packed cells. Plasma is 
essentially the same as serum, but is obtained by centrifuging the blood without clotting. Plasma 
therefore contains all of the clotting factors, including fibrinogen. (Wikipedia, 2011) 
 
Most laboratories are highly automated and use assays that are strictly quality controlled. Large 
med-labs will accept samples for up to about 500 different kinds of tests (LifeLabs, 2011). A 
portion of these tests is usually referred to other labs, as few labs maintain the capability to do the 
full array of tests.  
The Sub-specialty of Immunology  
Clinical immunology is the study of diseases caused by disorders of the immune system (failure, 
aberrant action, and malignant growth of the cellular elements of the system), as well as diseases 
of other systems, where immune reactions play a part in the pathology and clinical features. 
Immunology also studies ways to prevent transplant rejection. (Wikipedia, 2011) 
 
The diseases caused by disorders of the immune system fall into two broad categories: 
immunodeficiency, in which parts of the immune system fail to provide an adequate response, 
examples include chronic granulomatous disease; and autoimmunity, in which the immune 
system attacks its own host's body, examples include systemic lupus erythematosus and 
rheumatoid arthritis. Other immune system disorders include different hypersensitivities, in which 
the system responds inappropriately to harmless compounds, e.g. asthma and other allergies, or 
responds too intensely [Wikipedia, 2011]. 
  
The client’s specific interests fall in the areas of autoimmunity and allergy. Both classifications of 
disease are very significant. Autoimmune diseases, specifically rheumatoid arthritis, are the 
leading cause of disability in the population, and are increasing as the population ages. Allergies 
now affect a large and increasing portion of the population.  
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 Diagnostic laboratory testing is a vital complement to clinical expression (patient symptoms) in 
autoimmune cases, as it helps to produce a conclusive diagnosis even when clinical expression is 
vague. This enables early detection and treatment, which is vital to improving the quality of life 
(rheumatoid arthritis and lupus) and survivability outcomes (lupus) for patients.  
 
In the case of allergies, diagnostic testing is also very important as it not only provides an 
alternative to allergy specialist delivered skin testing and oral challenge, but can also reduce or 
eliminate incorrect identification of allergens as a result of cross-reactivity, and predicts reaction 
severity to specific allergens. The latter enables a greatly improved quality of life, for example, 
by opening up a much broader range of food menu choices for people that were erroneously 
identified as allergic to peanuts due to cross reactivity but were actually allergic to birch pollen. 
2.2.4.2 Hematology 
Hematology (or hematopatholgy) is a branch of clinical medicine concerned with the analysis of 
blood, the blood forming organs and blood diseases. Blood diseases affect the production of 
blood and its components which include red blood cells, white blood cells, platelets and blood 
proteins. Blood diseases also affect the mechanism of coagulation.    
 
Complete blood counts (CBC’s) are amongst the most commonly performed med-lab tests in 
medicine. Abnormally high or low counts may indicate the presence of many forms of disease, 
hence blood counts can provide an overview of a patient's general health status. 
 
Med-lab tests under the discipline of hematology can be grouped into sub-specialities of 
haematology and hemostasis (coagulation).     
The Sub-specialty of Coagulation 
Coagulation is the complex process by which blood forms clots. Coagulation begins almost 
instantly after an injury causes damage to the endothelium (lining of the blood vessel). Exposure 
of the blood to proteins, such as tissue factor, initiates changes to blood platelets and the plasma 
protein fibrinogen, a clotting factor. Platelets immediately form a plug at the site of injury; this is 
called primary hemostasis. Secondary hemostasis occurs simultaneously – proteins in the blood 
plasma called coagulation factors or clotting factors respond in a complex cascade to form fibrin 
strands which strengthen the platelet plug. [Wikipedia, 2011] 
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Disorders of coagulation can lead to an increased risk of bleeding (hemorrhage) or obstructive 
clotting (thrombosis). Diagnostic tests are vital in detecting disorders as well as in managing 
treatment.   
 
One example of an important diagnostic test is Prothrombin Time (PT). It is used to evaluate the 
ability of blood to clot properly by evaluating the function of coagulation factors, and has 
numerous applications including pre-surgery screening of patients for any previously undetected 
bleeding disorders.  
  
An example of a test employed in management of chronic disease is the International Normalized 
Ratio (INR). INR is used to monitor the effectiveness of blood thinning drugs such as warfarin 
(Coumadin). These anti-coagulant drugs help inhibit the formation of blood clots. They are 
prescribed on a long-term basis to patients who have experienced recurrent inappropriate blood 
clotting. This includes those who have had heart attacks, strokes, and deep vein thrombosis 
(DVT). Anti-coagulant therapy may also be given as a preventative measure to patients who have 
artificial heart valves, and on a short-term basis to patients who have had surgeries, such as knee 
replacements. The anti-coagulant drugs must be carefully monitored to maintain a balance 
between preventing clots and causing excessive bleeding. (Lab Tests Online, 2011) 
 
2.2.4.3 
2.2.4.4 
Microbiology 
Microbiology is a branch of clinical medicine that studies microorganisms, including bacteria, 
viruses, fungi and parasites, which are of medical importance and are capable of causing diseases 
in human beings. 
 
Consistent with the above definition, med-lab tests under the discipline of microbiology can be 
grouped into the sub specialities of: bacteriology, the study of bacteria; virology, the study of 
viruses; mycology, the study of fungi; and parasitology, the study of parasites.      
Molecular Diagnostics 
Molecular diagnostics is an emerging field of laboratory medicine that can be applied to various 
sub-specialities, often as a complement or substitute for techniques applied in clinical 
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 microbiology, including: oncology, the study of cancers; virology; bacteriology; and blood 
screening tests (Roche, 2011). 
 
Molecular diagnostics employs a number of technologies including DNA sequencing and 
genotyping, and polymerase chain reaction (PCR) technology. The latter is used to rapidly 
replicate a single specific strand of DNA, or RNA, to quantities sufficient for accurate laboratory 
analysis. Two examples of the applications and utility of genotyping and PCR, respectively, 
follow:  
 
Detection of human papillomavirus (HPV): in addition to detecting the virus, genotyping can 
identify high risk HPV types known to be associated with progression to cervical cancer. This 
provides a far more specific test (one that produces less false positives) than traditional methods.  
 
Rapid detection of disease causing pathogens: PCR can detect pathogens, such as tuberculosis, 
fungi, and bacteria that can lead to life-threatening sepsis, much faster than traditional 
microbiology methods that have much longer incubation times.  
2.2.4.5 
2.2.4.6 
Histology 
Histology (or Histopathology) is a branch of clinical medicine that employs microscopic 
examination of tissue in order to study the manifestations of disease. Specifically, it involves the 
examination of a biopsy or surgical specimen by a pathologist, after the specimen has been 
processed and histological sections have been placed on glass slides. (Wikipedia, 2011) 
 
Histology is a vital tool used in the confirmation of the presence of cancer in specific tissues.  It is 
also used to define surgical margins (where to cut) for the removal of cancers, and in the study of 
heart attacks.  The two main sub-specialities of Histology can thus be classified as Oncology and 
Myocardial Infarctions (heart attacks).   
Cytology 
Cytology (or Cytopathology) is a branch of clinical medicine that studies and diagnoses diseases 
at the cellular level. Cytology is generally used on samples of free cells or tissue fragments, in 
contrast to histopathology, which studies whole tissues. Cytology samples are often smeared 
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 across a glass microscope slide for subsequent staining and microscopic examination by a 
pathologist. 
 
A common application of Cytology is the Pap Smear, which is used as a screening tool to detect 
precancerous cervical lesions. Cytology is also commonly used to investigate: thyroid lesions; 
diseases involving sterile body cavities, such as that which surrounds the lungs; and a wide range 
of other body sites (Wikipedia, 2011). The two main sub-specialities of Cytology can be 
classified as Oncology and Other.  
 
2.3 Strategic Groups 
The intent of this section is to identify groups of rival organizations that have similar competitive 
strategies and positions in the industry. Identification of such strategic groups is important 
because it identifies which organizations are in direct competition, identifies groups whose 
competitive positions may be tenuous, and helps to identify barriers that inhibit movement from 
one strategic group to another (mobility barriers). (Shapiro, 2010).   
 
As noted above, public hospitals primarily service the inpatient customer group, while private 
community labs service the majority of outpatients. This suggests that industry rivals can be 
divided into public and private service providers. To explore this inference further, the 
organizations servicing the med-lab industry in BC are mapped against two strategic dimensions: 
inpatient versus outpatient balance, and geographical scope. Geographical scope is calculated 
based on the proportion of regions serviced, out of a total of five. 
 
Figure 2.3 reinforces the inference that there are two main strategic groups, public (yellow 
grouping) and private (cyan grouping), in the med-lab industry in BC. Figure 2.3 also shows that 
there is a major gap in positioning between the public and private groups, on the axis of 
“percentage of outpatients”. There is also a significant gap between the more geographically-
focused providers (BC Bio and Valley Labs), and LifeLabs on the geographic scope axis, 
suggesting a differentiated position for LifeLabs. Finally, the figure clearly demonstrates that 
PHSA has a highly differentiated service offering, and as such does not fit into either strategic 
group, although it has a closer association with the public group, based on its ownership. 
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 Figure 2.3:  Strategic Group Map 
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Figure 2.3 reinforces the inference that there are two main strategic groups, public (yellow 
grouping) and private (cyan grouping), in the med-lab industry in BC. Figure 2.3 also shows that 
there is a major gap in positioning between the public and private groups, on the axis of 
“percentage of outpatients”. There is also a significant gap between the more geographically-
focused providers (BC Bio and Valley Labs), and LifeLabs on the geographic scope axis, 
suggesting a differentiated position for LifeLabs. Finally, the figure clearly demonstrates that 
PHSA has a highly differentiated service offering, and as such does not fit into either strategic 
group, although it has a closer association with the public group, based on its ownership. 
 
To better understand the public and private groups, Table 2.3 describes the strengths and 
weaknesses of the players within the groups. The public group is characterized by inpatient focus, 
high political influence, low-medium scale, and low flexibility (the ability to scale operations up 
or down). The private group is almost the opposite, characterized by outpatient focus, low-
medium political influence, high scale and high flexibility.  
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Table 2.3:  Strengths and Weaknesses of Competitors in British Columbia 
 Competitor Strengths Weaknesses 
Public Hospital 
Laboratories 
(in each of the 
health 
authorities)  
9 Political Strength 
9 Public backing and sympathy 
9 Preferential access to new licenses
9 Breadth of testing  
× Lack scale 
× Difficult to scale up and down 
× Strong union influence 
× Inpatient focus 
× Long wait times for outpatients 
× Slow decision making 
× Lack of fiscal accountability 
BC Biomedical 
Laboratories 
9 Strong incentive alignment; owned by a
group of physicians 
9 Strong ties to other physicians   in 
Fraser Health Authority 
9 Strong presence in BCALP* 
9 Small business feel 
9 Breadth of testing 
× Lack scale 
× Limited capability to support broad 
collection network 
× Slow decision making 
× Limited business expertise 
× Exclusively outpatient focused 
 
LifeLabs 9 Largest scale and most cost  efficient 
9 National infrastructure 
9 Fast (relatively) decision   making 
9 Access to capital (via Borealis) 
9 Breadth of testing 
× Big business image 
× Lacking influence in BC physician 
community  
× Viewed as a threat by the public 
sector 
× Exclusively outpatient focused 
 
Valley Medical 
Laboratories 
9 Very strong incentive alignment; owned
by small group of physicians, 
directly    engaged in the business
9 Nimble and fast decisions  
× Mom & pop shop 
× Small scale  
× Outdated IT systems 
× Low automation 
× Low business expertise 
× Exclusively outpatient focused 
Note “*”: BC Association of Laboratory Physicians (BCALP) 
[Source: Author] 
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 2.4 Industry Supply Chain 
The following discussion describes the flow of goods and services for the med-lab industry in 
BC, from raw inputs through to final customers. This section will explain how the industry is 
organized, how market power and profits are distributed along the supply chain, the degree of 
vertical integration of the industry, and how the vertical structure of the industry may be changing 
(Shapiro, 2010).  
2.4.1 Overview 
In simple terms, the key steps in the med-lab supply chain are specimen (blood, urine, other) 
collection, specimen transport, specimen analysis, result interpretation, result communication, and 
diagnosis and treatment of the patient’s illness. Hence, the ultimate benefactor or final customer 
of the service is the patient. As previously discussed, although patients are the end customer, 
doctors choose the appropriate test(s), and the government pays for most tests via MSP. 
  
The inputs that enable the above described flow of service delivery are: procurement of 
instruments and consumables that enable collection and testing of specimens; attainment of 
government licences to open transfer or expand collection centres and testing laboratories; and 
attainment of ongoing quality accreditation through the Diagnostic Accreditation Program 
(mandatory) and ISO (optional). 
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 Figure 2.4: Supply Chain for the Medical Diagnostic Laboratory Industry in BC 
 [Source: Author] 
 
2.4.2 Key Groups of Participants  
There are four key groups that make up the above described supply chain: government and non-
government organizations that are responsible for licensing and accreditation; platform suppliers 
that supply instruments, reagents and service; integrated laboratories; and physicians and 
surgeons.  
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 2.4.2.1 
2.4.2.2 
Licensing and Accreditation Granting Bodies 
Licenses for med-lab collection or testing in BC are granted by the Medical Services Commission 
(MSC), which is part of the BC Ministry of Health Services. The MSC not only screens new 
licence applications and licence transfer applications (location change), but also screens 
applications for changes in operating hours and number of phlebotomists (medical technicians 
that collect blood) at a collection site.  
 
Licences can only be granted to med-lab testing facilities that have been accredited by the 
Diagnostic Accreditation Program (DAP). The DAP is governed by the DAP Committee, which 
is appointed by the College of Physicians and Surgeons of British Columbia (CPSBC). DAP has 
a Laboratory Medicine specific accreditation program which is comprised of audits (DAP term: 
surveys) and independent external quality assurance testing (DAP term: proficiency), and 
includes specific requirements for each of the following areas: sample collection, transport, and 
order entry (accessioning); chemistry; hematology; transfusion medicine; microbiology; anatomic 
pathology (histology and cytology); and point of care technology (POCT).  
 
This group provides value to the community by assuring that the laboratory services provided to 
the public meet stringent medical quality standards.  
Platform (Instrument, Consumable and Service) Suppliers 
Platform suppliers provide test instruments, associated service, and a wide array of consumables 
from needles and vials, used in collection, to media and chemicals (reagents), consumed during 
testing. Platform suppliers provide extensive value in the form of test and product innovation, as 
well as process automation. They deliver improved medical utility, which often translates to 
improved patient outcomes, as well as lower operating cost. Since they have a global customer 
base, platform suppliers can also be a valuable source of information on global health trends and 
the success of new tests and technologies in other jurisdictions.  
 
Most platform suppliers have speciality areas, and as such the composition of the supplier groups 
varies significantly from one medical sub-specialty to another.  For Coagulation, the lion’s share 
of product is supplied by two, multi-billion dollar organizations: Siemens, partnered with 
Sysmex, and Beckman Coulter, partnered with Instrumentation Laboratories and recently 
acquired by Danaher. For allergy, there are also few suppliers, primarily Phadia and Euroimunn. 
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 However, these latter organizations are far smaller, operating in the hundreds of millions of 
dollars revenue range (at least one order of magnitude smaller than their coagulation cousins). 
This smaller size places them much closer to the magnitude of their customers’ (integrated 
laboratories) operations. For autoimmunity the range of suppliers is once again small: Phadia, 
Euroimmun, Biorad, and Diasorin, and their scale is similar to that of allergy (with some supplier 
overlap). (Links to the websites of each of the suppliers discussed in this paper can be found in 
the References.)     
2.4.2.3 Integrated Laboratories 
Integrated laboratories, public or private, have the greatest span of vertically integrated activities 
in the med-lab supply chain. They provide a full array of services, including: specimen collection, 
via a network of patient service centres (PSC’s), at which patients can visit to drop off their 
samples or have them collected, and via mobile collection services; transport, pick up from 
PSC’s, mobile collection service hubs, physician offices, and other care facilities; testing, across a 
broad range of subspecialties; interpretation of results by lab physicians; communication of 
results to the requesting physician; and on-demand consultation to aid in result interpretation by 
the requesting family physician or specialist.  
 
Private providers, such as LifeLabs and BC BioMedical Laboratories offer the full array of 
services described above, as does Valley Medical Laboratories on a much smaller scale. Public 
hospitals also offer a large portion of the services described above, although their focus depends 
on geography, or more specifically on population density. Hospitals in more remote health 
regions such as the Interior Health Region or the Northern Health Region carry out a broad array 
of the services described above, including many outpatient oriented services. Hospitals in urban 
settings tend to focus more on inpatients, as outpatients are comprehensively serviced by private 
labs.    
 
Integrated labs provide value to the patient by providing them with a convenient, reliable, high 
quality health service. They also provide utility to physicians by informing their diagnostic 
decisions with reliable test results and providing them with additional consultation to interpret 
results should they need it.  
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 Inpatient and outpatient services have not been strongly distinguished above, as the supply chain 
for inpatients is made up of very similar components to those of the supply chain for outpatients. 
The only major difference is that an inpatient environment, such as a hospital, has all of the above 
described elements as well as additional substitute (e.g. point of care testing) and complementary 
services (e.g. diagnostic imaging, electrocardiogram (ECG), pharmacy, etc.) which are fully 
integrated into its service offering.   
2.4.2.4 Family Physicians and Specialists 
There are approximately 5,000 Specialists and 5,500 General Practitioners practicing in BC 
(CPSBC, 2010).  Physicians compare and contrast test results and lab physician interpretation 
against patient symptoms (clinical presentation) in order to effectively diagnose disease and 
prescribe treatment.   
 
Physicians also play a very strong role as agents for the buyer (patient), advising or dictating the 
type of tests to be ordered and signalling their preference for service provider through the use of 
preferred service provider requisition forms.  
2.4.3 Market Power and Rent Capture 
The scarcest resources, and thus areas of greatest rent capture potential, are: the physicians 
themselves; the government licences to operate specimen collection centres and test analysis 
laboratories; and the platform technologies and associated intellectual property that enable 
testing. This will be elaborated on in Section 2.6: Market Structure. 
2.4.4 Changes in the Vertical Structure 
The emergence of point of care technology (POCT), which enables remote or decentralized 
testing, could signal the beginning of the disintermediation of the med-lab supply chain. POCT is 
an emerging technology that enables laboratory testing to be performed effectively on a small 
scale. Although the cost per test is still high, it offers great utility by providing rapid test results 
directly at the point of care.  POCT has the potential to enable the replacement of the large, high 
volume, and very expensive analysers used by centralized integrated laboratories by small, far 
less expensive, desk-top test units that would be deployed as a large decentralized network.   
 
 18
 2.5 Industry Boundaries 
 
The previous discussion implicitly assumed that the relevant boundary for the med-lab Industry is 
the province of British Columbia. The following section tests the validity of this assumption.   
 
To assess the boundaries of the industry it is useful to start with the customer perspective. 
Outpatients value convenience and thus prefer to have services within their communities as it 
minimizes inconvenience to them. Patients requiring acute care (inpatients) primarily value 
quality of care and speed of service delivery. Convenience is not a significant consideration. 
Despite convenience not being highly valued by inpatients, most acute care services are available 
within the boundaries of their home health authority. Thus, from a patient perspective, the market 
appears very local in nature.  
 
Looking beyond the customer perspective, however, reveals a different picture. Funding 
providers, regulators and service providers all operate at the health region or provincial level. In 
the case of service providers, aggregation of smaller local markets into larger markets is critical to 
achieving the scale economies required to provide cost efficient health service to the public. 
Private labs in particular employ large centralized laboratories to achieve the volumes required to 
operate at minimum efficient scale. Government control of access to services, via licensing, and 
cost, via fee schedules under MSP, is also administered by the provincial government at a 
provincial level.  
 
Hence, given the large minimum efficient scale and provincial regulation of the industry, it is 
reasonable to continue to assume a provincial boundary for the medical diagnostic laboratory 
industry. Expanding the boundary to include multiple provinces, or to a national level is not 
considered reasonable as market structures vary considerably from province to province.  
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 2.6 Market Structure 
2.6.1 Market Size and Market Share 
The medical diagnostic laboratory services industry has been in existence for more than fifty 
years in British Columbia, far more if inpatient only services are considered.1 .Steady 
consolidation has been occurring in the industry throughout the last three decades, including an 
accelerated burst in the 1990’s, and has now resulted in the survival of only three labs of any 
significant scale (excluding public labs),– LifeLabs, BC Biomedical Labs, and Valley Medical 
Labs. These private labs together service approximately 67% of the outpatient market 
(approximately $200 million per year), with LifeLabs, BC Bio and Valley holding 39%, 24%, ad 
4% of the outpatient market respectively (Medical Services Commission, 2009). Public labs 
service the remaining 33% share (approximately $100 million per year).  
 
New tests are made available to the public every year. However, the proportion of the overall test 
menu which changes is very small. Test demand continues to grow at a slow but steady pace of 
approximately 2 to 3% per year (LifeLabs, 2011). This growth can be attributed to test demand 
increasing as the demographic mix shifts towards the elderly, as well as the increasing medical 
focus on early detection and effective treatment of both acute and chronic diseases, which is 
assisted by diagnostic testing and therapeutic drug monitoring.  
2.6.2 Market Structure 
As previously described, the medical diagnostic laboratory industry in BC is made up of three 
major private laboratories and six public health authorities. Despite the existence of a total of nine 
major entities providing med-lab service, the number of major players in a region rarely exceeds 
three or four because service providers focus geographically, as described in Table 2.2. At a local 
level the number of players servicing a specific community, e.g. Central Surrey, is even smaller, 
                                                     
1 Research conducted in support of this paper was unable to determine the total level of funding for inpatient and 
outpatient laboratories in BC. However, Ontario data suggests that total inpatient hospital laboratory funding is 
approximately 50% greater than total outpatient funding   (Ontario Association of Medical Laboratories, 2007). If 
the same factor was applied to the BC numbers, it would mean an inpatient funding level of approximately $450 
million per year, taking the total public share of the combined, in-patent and outpatient, market up to about 73% of 
total spending on lab services, with 27% spending from private sources  Although this percentage may be grossly 
over or under-stated, it demonstrates that the inpatient market is substantial and needs to be considered to arrive at 
true expressions of market share for the combined market. 
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 rarely exceeding two. This is because of the licensing restrictions placed by government (through 
the MSC) on the density of specimen collection centres.  
 
According to current MSC guidelines, the following conditions must be met to gain approval to 
open a new specimen collection centre: the application has to be supported by five physicians; 
each phlebotomy (blood collection) chair provisioned for the site needs to be assumed to handle 
thirty-five patients per day; and the distance between the proposed site and any other collection 
site, public or private, cannot be less than thirty minutes on public transit. If two applications are 
simultaneously placed by two providers for the same area, they are generally considered on their 
merits. However, as a rule of thumb, public trump private applications, usually because public 
applications are associated with hospitals or acute care centres. Once an application is approved, 
the applicant is effectively granted an eighteen month option to exercise the licence. During this 
eighteen month period, other applications for the same area will not be considered by the 
government. MSC application rules do change periodically, and currently require stronger 
expressions of community need to justify additional capacity than in the past. (LifeLabs, 2011) 
 
In addition to controlling access to services via licensing of specimen collection centres, the 
government controls med-lab test prices by setting MSP fee schedules. The process for setting 
fees is shown in Figure 2.6 below. The first step in the process is the drafting of recommendations 
for changes, additions or de-listings of tests by the respective science sections of the BC 
Association of Laboratory Physicians (BCALP). The recommendations from the science sections 
describe the clinical value and cost per test to demonstrate value to the government. Those 
recommendations are then screened by the BCMA, in competition with other, non-laboratory 
medicine recommendations, and successful recommendations are taken forward as fee 
applications.   
 
Thus, although fee schedules (prices) for med-lab testing are ultimately determined by the 
government, via MSC, the British Columbia Medical Association (BCMA) has a significant 
influence on the portion of total medical funding that is appropriated by laboratory medicine. 2  
 
                                                     
2  Why is the government so involved in the med-lab industry? A likely explanation follows: First, it is running an 
insurance plan, MSP, covers 100% of the test costs for the patient. Second, it appreciates that economies of scale 
and scope are very significant in the industry and as such a small number of service providers makes sense. The first 
issue drives it towards limiting supply so that the service is not over-consumed. After limiting volume it places itself 
in danger of oligopoly or duopoly pricing, by virtue of the second issue, and thus attempts to regulate price down to 
a more socially efficient level.  
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 Figure 2.6: Application Process for Changes to Laboratory Testing Fees 
[Source: Kelly, 2011] 
 
In summary, the market structure of the industry can be described as consisting of local 
oligopolies with government price (test level) and volume controls (patient service centre 
licensing). As a result, the competition in the industry is mainly based on service delivery (turn-
around-time (TAT)) and quality via the Diagnostic Accreditation Program. TAT is a critical 
characteristic as it has implications for test integrity, patient outcomes, and patient and physician 
convenience. 
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 3: Analysis of the Medical Diagnostic Laboratory Industry 
 
The preceding chapter has described the medical diagnostic laboratory industry in BC in detail, 
including services and customers, industry segmentation, strategic groups, industry boundaries, 
supply chain and market structure. 
 
To provide the client with insight into the external environmental factors that are most likely to 
influence long-run profitability and risk, this chapter will analyse those forces that affect industry 
profitability now and in the future. The analysis will isolate forces specific to the medical sub-
specialties of allergy, autoimmune, and coagulation, so as to enable the development of specific 
recommendations for the client’s most urgent decisions.  
 
The following analysis is composed of a life-cycle analysis, demand and cost analysis, Porter’s 
Five Forces analysis (Porter, 1980), and a political landscape analysis. Life-cycle and demand and 
cost analyses are used to include considerations that may be deficient in a stand-alone Porter’s 
Five Forces analysis. A political landscape analysis concludes the section to ensure that any 
important political climate factors that were omitted by the preceding analyses are addressed. 
 
3.1 Life Cycle Analysis 
 
Assessing lifecycle is useful for confirming the current state of the industry and roughly 
predicting what is likely to happen next. 
 
The long history, slow growth, slow test schedule turnover, and provider consolidation described 
in Section 2.6 are all characteristics that are consistent with the mature phase of the industry 
lifecycle. Thus, the industry as a whole can be described as mature. Life cycle theory suggests 
that in a mature industry revenue is likely to be flat or declining, and that cash flow is likely to be 
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 flat, assuming an increased emphasis on cost control. It also suggests that there is a high degree of 
standardization in the industry.  
 
Since the label of mature is not true for all industry segments (the clearest example being 
Molecular Diagnostics which is in the embryonic phase), it is prudent to assess lifecycle 
specifically for the segments (sub-specialities) being studied. These include allergy, autoimmune, 
and coagulation. The brief analysis presented in Table 3.1 demonstrates that autoimmune and 
coagulation segments are consistent with the maturity phase, while allergy has growth phase 
characteristics.  
 
Table 3.1:   Life-cycle Phase Analysis by Industry Segment (Medical sub-specialty)  
Segment Current 
Characteristics 
Current 
Phase 
Implied Future State 
Allergy • Increasing prevalence 
amongst, and awareness 
from the population 
• Alternatives to traditional 
(Skin Prick) tests gaining 
increasing acceptance 
Growth • Continued growth in 
demand and revenue 
• Entry of new instrument 
and technology providers 
is likely 
 
Autoimmune • Slowly increasing test 
demand 
Maturity • Continued slow growth in 
demand 
• Small, stable supply base 
Coagulation • Slowly Increasing test 
demand 
Maturity • Continued slow growth in 
demand 
• Small, stable supply base 
 
3.2 Demand and Cost Analysis 
 
Demand and cost analysis provides insight into the factors that determine the value created by 
med-lab services (the difference between the willingness to pay for, and the costs of providing the 
services), as well as into the effects of price and supply regulation. 
 
The following analysis is split into two sections. The first examining factors that influence 
demand (willingness to pay) and the second examining factors that influence cost. 
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 3.2.1 Demand Analysis 
3.2.1.1 
3.2.1.2 
Income 
Incomes affect demand. A good or service can be either classified as normal, if its consumption 
increases as income rises, or inferior, if its consumption increase as income falls.   
 
As discussed in section 2.2.3 the funding for the Medical Laboratory industry can be split into 
three major sources: Public Funding (Global), Public Funding (Fee Schedule MSP), and Private 
Funding. For the consumer (patient) this translates respectively to three scenarios: emergency 
treatment; non-emergency screening, diagnosis or management of disease; and higher value add 
screening or diagnosis of disease.  
 
Since the first two funding sources, global hospital funding and MSP, are public insurance the 
patient’s income has no material effect on consumption. However, government income does. The 
greater the government’s tax revenues, the greater their willingness to spend more on med-lab 
services. Under private funding, med-lab testing again behaves like a normal service. However, in 
this instance demand increases as patient income rises. Thus, in aggregate, diagnostic med-lab 
service in BC exhibits the characteristics of a normal service.  
 
Since tax revenues are currently flat and are likely to remain flat or decline due a shrinking labour 
force, incumbents in the med-lab industry are likely to experience a reduction in willingness to 
pay from their largest buyer, the BC government (BC Stats, 2011).   
Prices of Related Goods 
The next determinant of demand is the price of related goods and services, specifically 
substitutes, for which an increase in the price of one good or service results in the increase of 
demand for the other, and complements, for which the increase in price of one good or service 
results in a decrease of demand for the other.  
  
Demand for med-lab services is influenced by the price of complementary services such as 
physician consultations, electrocardiogram (ECG), blood pressure monitoring, diagnostic 
imaging, e.g. magnetic resonance imaging (MRI), X-Ray, and pharmacy. Urgent and basic 
physician consultations, ECG, blood pressure and diagnostic imaging services are publicly or 
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 privately insured, as are some pharmaceuticals. As a result, they have a negligible effect on 
consumer demand but can have a significant effect on government demand. Publicly funded med-
lab services are affected by price changes in the suite of complementary medical services 
managed by the BCMA, as previously described in Figure 2.6. Elective screening services, such 
as MRI scans are often privately funded and can be very costly, and thus have a noticeable affect 
on consumer demand. For example, increases in elective MRI price can have an adverse impact 
on demand for private pay med-lab screening services and vice-versa, as they impact the 
consumer’s willingness and ability to pay.  
 
In summary, demand for both publicly funded and privately funded med-lab services is 
susceptible to price changes in complements. However, incumbents are unlikely to be 
dramatically affected by complements as the prices of the various services are relatively stable. 
 
Demand for med-lab services is also influenced by the price of substitute services. Publicly 
funded med-lab services are strongly, potentially dramatically affected by price changes in 
substitutes. Some examples follow.  
 
Screening: If genomic screening technology made cost effective and accurate predictive 
screening possible, the government would likely shift substantial budget funding from current 
med-lab screening technology to genomics. The lower the price of such testing, the more 
dramatic the shift.  
 
Chronic disease management: If the price of POCT became low enough and the reduced load on 
the hospital system as a result of more effective disease management were appreciated and 
monetized, the government would likely agree to increased MSP fees for med-lab tests that were 
offered on distributed basis throughout the community via POCT.  
 
Infectious diseases: If the price of molecular diagnostic identification of pathogens drops enough, 
the government is likely to increase MSP funding of the technique, which is faster and more 
specific than traditional methods, leading to more effective disease monitoring and treatment.   
 
Privately funded services are also affected by price changes in substitute services. These include 
naturopaths who may have a different usage rate and mix of med-lab tests compared to 
physicians, physician administered tests such as the skin prick test conducted in house by allergy 
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 specialists, and POCT tests. If naturopaths were to reduce their fees, an additional portion of 
consumers of physician service would shift to naturopaths, thus changing test demand and mix. If 
private pay allergy tests that are more specific and less onerous (one finger prick for the med-lab 
test versus multiple skin pricks for physician administered test), were to be offered at a low 
enough price, consumers would pressure allergy specialists to provide access to the test, thus 
increasing demand for med-lab testing. If POCT based testing (using numerous small test 
instruments widely distributed throughout the health network or patients’ homes) was provided to 
consumers for chronic disease management, then this would reduce time to results and would 
require smaller blood samples, increasing willingness to pay.  
 
In summary, demand for both publicly funded and privately funded med-lab services will be 
affected by changes in the price of substitutes. Changes in the prices of two substitutes are likely 
to have a dramatic affect on demand:  it is likely that incumbents will need to face the threat of 
broad adoption of POCT and molecular diagnostics during the 5-10 year planning horizon.   
3.2.1.3 Advertising and Consumer Tastes 
Demand for med-lab services increases with increased advertising, however its effect is usually 
limited to a very narrow set of tests. For example, increased discussion of Vitamin D deficiency 
in the media recently has significantly increased the demand for Vitamin D testing. Also, 
LifeLabs education of doctors raised the awareness of the value of screening for colorectal cancer 
using the FIT method, and has increased the general awareness of colorectal cancer in the patient 
population, resulting in increased demand.  
 
Although the media does affect med-lab demand, the med-lab industry itself does not advertise in 
the media. Its advertising consists of the education of physicians regarding the existence and 
quality of a test (informative advertising) through seminars at conferences, visits to physician’s 
offices and newsletters. Med-lab patient service centres and some physicians’ offices also make 
test flyers available to patients. 
  
Since advertising is primarily delivered in the form of physician education, it is important for 
incumbents to stay active in physician forums, to stay connected to physician (customer agent) 
needs and to effectively communicate the value of new, superior tests and the rationale for 
retirement of old, inferior tests.   
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 3.2.1.4 Population 
General Provincial Trends 
As of October 1, 2010, the population of BC had reached 4,551,853 people. Over the previous 
year the provincial population grew at a rate of 1.5%, second only Saskatchewan at 1.53% (BC 
Stats, 2010).  According to BC Stats, the population in BC is likely to expand by approximately 
1.6 million people by the year 2036, at an average growth rate of 1.2% (compared with 1.6% for 
the last 27 year period).  
 
Some highlights from the BC Stats 2036 projection are: Growth will be driven by immigration 
with half the population 45 or older, an approximately 4 year increase from the current median 
age.  There will be a reduction in the relative size of the under 18 age group, from about 20% to 
about 17%, more seniors than children and a continued increase in female to male ratio, from 
100:98.5 now to 100:97.  There will be a relatively smaller labour force, about 65% of the 
working age population compared with current 70%; and the strongest growth will be in the 
Lower Mainland but the youngest population will be in the North East, driven by jobs in energy 
sector.  The Okanagan population will still be older than the provincial average, however by a 
smaller amount, about 2 years compared to the current 4 years, and senior migration to 
Vancouver Island will continue.   
 
Although BC is the second fastest growing population in Canada, the rate of growth is quite 
modest and unlikely to have a significant impact on demand. However, shifts in demographics are 
likely to increase demand for tests associated with chronic disease monitoring due to an increased 
proportion of seniors, as well as for risk factors and lifestyle factors due to an increased 
proportion of those of middle age in the population. Demographic changes are also likely to 
decrease microbiology test demand due to a decrease in youth population. These shifts are likely 
to be especially pronounced on Vancouver Island. 
Sub-specialty Specific Trends – Autoimmune and Coagulation 
Since the population is ageing, the segments of autoimmune and coagulation are likely to grow in 
the range of 3-5% per annum. Growth in autoimmune and coagulation will be driven by the 
increase in rheumatoid arthritis and heart and stroke disease respectively. 
 28
  
Sub-specialty Specific Trends – Allergy 
The American Academy of Allergy, Asthma and Immunology estimates that from 2 to 4% of 
children and 1 to 2% of adults have allergic reactions to food (AAAAI, 2011). In a 2003 study of 
the prevalence of peanut allergy in 4339 primary-school children in Montréal, the prevalence of 
peanut allergy was found to be 1.50%. (Kagen, 2003)  
In England, there has been a more than two fold increase in the prevalence of peanut allergies 
between 2001 and 2005, an almost 50% increase in the presence of hayfever, asthma and eczema 
together between 2001 and 2005, and a three fold increase in anaphylaxis requiring hospital 
treatment between 1994 and 2004 [Wikipedia, 2011].     
Although allergy is currently a very small portion of the med-lab market, the above mentioned 
trends suggest that annual growth rate of about 10% is not an unreasonable estimate. Thus, 
incumbents should invest in the development of broader allergy test capability. 
3.2.1.5 Other Factors 
Other events that have historically proven to have an impact on med-lab test demand include 
infectious disease scares, such as the 2009/2010 H1N1 flu pandemic, and major sporting events 
such as the 2010 Vancouver Winter Olympic Games.  
 
In the H1N1 case, people did not want to visit their physicians for fear of contracting the flu and 
thus withdrew from the market, thus reducing total test demand in the impacted months by about 
10% compared to the prior year (LifeLabs, 2011). Similar, but much more localized demand 
reducing effects have also been seen with Norwalk virus, mumps, and whooping cough. In the 
case of the Vancouver Winter Olympic Games, the negative effects of the games on access to 
medical facilities reduced demand for med-lab services by about 10% for the same period the 
prior year (LifeLabs, 2011).    
 
Incumbents need to recognize that exceptional events will continue to disrupt operations and 
consider the disruption mitigating benefits of a highly distributed system (such as POCT) in 
people’s homes or long term care facilities. This is especially relevant to chronic disease 
monitoring and the coagulation segment by extension.    
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 3.2.2 Cost Analysis 
3.2.2.1 
3.2.2.2 
Input Prices 
The main input costs for med-lab industry service providers are: materials costs, including 
reagents (chemicals), media such as tissue cultures, and collection vessels such as vials consumed 
in the process of testing; labour costs; transportation costs; test instrument costs; facilities costs; 
and licensing and accreditation costs.  
 
For incumbents, labour and materials costs are expected to remain flat, with increases offset by 
productivity gains. Transport costs are likely to increase in the long run as the price of oil 
continues to climb. Licensing costs are also expected to increase as adjacent sectors, such as 
diagnostic imaging, have recently had competency scandals, increasing the likelihood of even 
stricter accreditation guidelines.  Thus, in aggregate, costs are expected to rise.  
 
Incumbents are thus advised to assess if they have sufficient expertise in cost control and cost 
reduction as these competencies will be critical to defending profits. 
Technology 
International health crises such as H1N1 and SARS have highlighted how disintegrated provincial 
and national health infrastructure is in Canada. As a result, the government is now very invested, 
both federally and provincially in developing a fully integrated system that allows for effective, 
nationally coordinated responses to crises, including pandemics and natural disasters. In non-
crisis times, such a system is expected to provide significantly improved productivity and quality 
of care by providing physicians with rapid access to patient history. Patient history would include 
med-lab test results, diagnostic imaging test results, consultation notes, and pharmaceutical 
history. This initiative is broadly termed Electronic Medical Records (EMR) and is a formally 
documented goal of the BC Provincial government (Ministry of Health Services, 2011). It is thus 
clear that centralized diagnostic databases will soon become an integral component of healthcare 
delivery. 
 
Since the government is unlikely to mandate a single proprietary EMR software solution, because 
it would make it susceptible to hold-up, it is important that incumbents become involved in the 
definition of interface specifications so that they do not end up with unworkable or extremely 
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 high cost interface requirements. Incumbents already involved in development of interface 
software should consider leveraging their competencies to build the middleware required to 
effectively interface with the government’s systems. One example of an existing interface product 
is Excelleris, an electronic med-lab results reporting software co-developed by LifeLabs and BC 
Biomedical, which is now used by approximately 6,000 of the 12,000 doctors in British Columbia 
and provides patients with direct access to their results through a service called my e-Health 
(LifeLabs, 2011). Excelleris has the potential to lead to further interface development, possibly 
enabling connection between incumbent lab information systems (LIS, med-lab provider 
databases) and the provincial (PLIS, a centralized database for all public med-lab provider data in 
BC) or health authority lab information systems.  
 
EMR is likely to increase costs for incumbents. Although EMR-based test ordering is likely to 
improve ordering efficiency by reducing or eliminating problems associated with unclear or 
incomplete data on hard-copy requisitions, this will not be enough to offset the costs of 
developing interfaces and sharing information.  
3.2.3 Demand and Cost Analysis Summary 
Stable or declining government revenues combined with an increase in the availability of 
substitute services are likely to place downward pressure on the demand for med-lab services.  
Continued population growth and aging is expected to offset this downward pressure in the 
segments of allergy and autoimmune. However, this is not the case in the segment of coagulation.  
   
Although materials and labour costs are likely to stay relatively constant, transportation and 
licensing costs are likely to drive an increase in input costs. Additional new input costs such as 
EMR interfacing are also likely to be imposed on incumbents by government. 
 
Therefore, although value created by the health system is likely to grow because of incremental 
advancements in the utility of med-lab services and improvements in the quality of physicians 
decision making (enabled by integrated data), the value added by med-lab incumbents is likely to 
go down because of a constant or reduced government willingness and ability-to-pay and an 
increase in input costs. 
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 Despite the predicted downward pressure on incumbent profitability, opportunities to capitalize 
on changes and create new value exist. For example, willingness to pay for POCT for chronic 
disease management is likely to be high, which will enable incumbent providers to diversify into 
POCT under MSP billing or to charge consumers for a premium mode of service delivery (private 
providers only), even if the government does not support funding POCT above the current 
conventional med-lab level.   
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 Table 3.2:  Med-lab Demand and Cost Analysis by Industry Segment 
 Segment Key Demand Shifters Key Cost  Shifters Key Price Factors 
Allergy ↓ Falling prices and 
increasing value of 
substitute services: 
e.g. skin prick test vs. 
allergy component 
testing; blood draw vs. 
finger prick (POCT).  
↑ Population: increasing 
allergy prevalence.  
↑ Prices of inputs: 
Transport, licensing, 
and proprietary 
reagent kits costs 
increasing in this 
segment.  
↑ EMR interface 
development 
 
• Regulators (BCMA / 
MSC) 
↑ New and Better 
Assays (Tests) 
↓ Emerging 
Technology 
 
Autoimmune ↓ Falling prices and 
increasing value of 
substitute services: 
e.g. blood draw at 
clinic vs. finger prick at 
home (POCT). 
↑ Population: e.g. 
Ageing population 
drives increase in 
rheumatoid arthritis. 
↑ Prices of inputs: 
Transport, licensing, 
and proprietary 
reagent kits costs 
increasing in this 
segment.  
↑ EMR interface 
development 
 
• Regulators (BCMA / 
MSC) 
↓ Emerging 
Technology 
Coagulation ↓ Falling prices and 
increasing value of 
substitute services: 
e.g. blood draw at 
clinic vs. finger prick at 
home (POCT). 
↑ Population: e.g. 
ageing population 
drives increase in 
blood clot 
management for heart 
and stroke. 
↑ Prices of inputs: 
Transport and 
licensing cost 
increasing in this 
segment. 
↑ EMR interface 
development   
  
↓ Regulators 
(BCMA/MSC) 
↓ Emerging 
Technology 
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 3.3 Porter’s Forces Analysis of Industry Attractiveness 
 
The preceding demand and cost analysis provides insight into factors affecting value created and 
prices in the industry. However, to develop a more comprehensive understanding of the business 
landscape it is necessary to analyse how the structure of the industry affects average profits today 
and in the future. The structure of the industry will be examined using the Porter’s Forces (threat 
of substitutes, threat of entry, buyer power, supplier power and rivalry). Each of the Five Forces 
will be assessed qualitatively for its threats to rents of the current incumbent firms, both now and 
in the most likely future. A qualitative conclusion will be drawn regarding the overall level of 
attractiveness of the industry and the most likely future state.  
 
Aspects of the Porter’s Five Forces that are common to all segments will be discussed first, 
followed by discussion of the unique characteristics of the sub-specialty segments: allergy, 
autoimmune and coagulation.     
3.3.1 Common Forces 
3.3.1.1 The Threat of Entry (low and stable)  
The threat that potential new entrants pose to an industry’s profitability depends primarily on  
entry barriers. The lower the barriers to entry, the greater the potential for new players to enter the 
industry if incumbents are earning above average rates of profit. “Entry barriers exist whenever it 
is difficult or not economically feasible for an outsider to replicate the incumbents’ positions, and 
usually rest on irreversible resource commitments.” (p.25, Ghemawat, 2010). 
 
There are extensive barriers to entry for the med-lab industry. First, government regulation 
(licensing) precludes new players from entering markets that are adequately served (under-served 
markets are generally very geographically dispersed and difficult to serve profitably). Scale 
economies require that an entrant attain significant scale in order to generate positive economic 
profits (rents).  Incumbents have extensive sunk costs in property, plant and equipment, including 
everything from patient service centres and transport fleets, through to laboratory facilities and 
test equipment. Scope economies require that an entrant offer a broad range of test services to 
amass enough total volume to effectively utilize the capacity of test equipment. Other incumbent 
advantages including a reputation for service quality, technological know-how and learning 
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 effects, priority access to raw material inputs, and existing ownership of some high traffic 
business locations. There are also high exit barriers associated with limited ability to liquidate 
highly specific assets and extensive severance costs due to a largely unionized workforce.  
 
Threat of entry can thus be summarized as low and stable across all segments, including allergy, 
autoimmune and coagulation.  
3.3.1.2 The Degree of Rivalry (low and stable)  
The degree of rivalry in an industry refers to the degree and nature of competition. It is affected 
by the number and relative size of competitors, the industry’s basic conditions, including how 
capital intensive it is, and behavioural determinants, such as high exit barriers, or association of 
high strategic value to market position. (Ghemawat, 2010) 
 
As described in section 2.6.2, the market structure of the industry can be described as consisting 
of local oligopolies with government price (test level) and volume controls (patient service centre 
licensing). Government price and volume controls on the publicly insured portion (more than 
95%) of the industry’s output mitigate price competition (LifeLabs, 2011). As a result, 
competition in the industry is primarily based on turn-around-time and quality, via the Diagnostic 
Accreditation Program. Even in the approximately 5% private pay portion, price competition is 
limited because value-added services are often differentiated.  
 
The non-price competition described above suggests that industry rivalry is low and likely to stay 
low, unless substantial reductions in regulation occur. Even in such an instance, rivalry is unlikely 
to escalate dramatically as capacity cannot be adjusted easily or quickly and incumbents have 
significant advantages. Thus, even a less regulated market would be unlikely result in significant 
price competition.  
 
Rivalry can thus be summarized as low and stable across all segments. 
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 3.3.2 Introduction to Segment-Specific Forces 
3.3.2.1 
3.3.2.2 
The Threat of Substitutes 
The threat that substitutes pose to an industry’s profitability depends on the price-to-performance 
ratios of the different types of products or services to which customers can turn to satisfy the 
same basic need. It is also affected by switching costs (Ghemawat, 2010).  
 
As prices of new, substitute technologies drop and capabilities improve, improving price-to-
performance ratios, the substitute threat will increase.  
 
Switching costs for the consumer (patient) differ substantially depending on whether new 
substitute tests become MSP funded or not. If all tests are MSP funded then shifts to more 
convenient and higher specificity tests will be demanded by most, if not all, patients. If new tests 
become privately funded then the value will need to be very clear and the shift is likely to affect a 
smaller portion of patients. Since physicians act as agents for patients, lower switching costs for 
physicians will directly translate to faster adoption of substitutes and indirectly improve the 
likelihood of MSP funding by way of physician endorsement through the BCMA.  
 
Since the price-to-performance ratios of substitutes vary by segment, threat of substitutes will be 
addressed segment by segment. 
Buyer Power 
Buyer power increases with the bargaining power of buyers and the price-sensitivity of buyers. 
Bargaining power is high when buyers are large and concentrated relative to rivals (med-lab 
service providers), few buyers purchase a large proportion of the industry volume, buyers can 
threaten backward integration, and when buyers have good information on rival pricing. Price 
sensitivity of buyers is high when the product is a high proportion of buyer’s costs, there are 
many similar products are available from rivals in the industry, there are substitutes with good 
price-to-performance ratio, and switching costs (relationship specific investments) are low 
(Shapiro, 2010). 
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 As previously discussed, despite the patient being the end user of services, they are only assumed 
to be the buyer for private pay services.  The BC provincial government is the buyer of all 
services delivered under MSP and other global funding mechanisms, and will thus be considered 
the main buyer. 
 
Since the government’s bargaining power and price sensitivity varies by segment, buyer power 
will be addressed segment by segment. 
3.3.2.3 Supplier Power 
Supplier power increases with the bargaining power of suppliers as well as the price insensitivity 
of rivals in the industry. Bargaining power is high when suppliers are large and concentrated 
relative to rivals (med-lab service providers), rivals in the industry purchase a small percentage of 
suppliers’ product; and suppliers can threaten credibly forward integration. Price insensitivity of 
buyers is high when there are few alternate suppliers or when product is differentiated, when 
there are few substitute inputs for the industry, and switching costs (relationship specific 
investments) are high (Shapiro, 2010). 
 
Since the supplier’s bargaining power and price insensitivity of rivals varies by segment, supplier 
power will be addressed segment by segment.  
 
The above notwithstanding, there is one universal issue that affects all suppliers across segments, 
that is, the increasing requirements to achieve US Food and Drug Administration (FDA) and 
Health Canada approval. Increased requirements for FDA and Health Canada approval of new 
med-lab equipment and tests will result in a reduced rate of innovation and diversity of available 
technology, as regulatory barriers to entry for platform suppliers become prohibitive for smaller 
players. For larger players, increased FDA requirements and wait time will result in acceleration 
of plans to consolidate assays onto “super-platforms” (large laboratory equipment capable of 
servicing a diverse range of med-lab segment requirements). The above described changes will 
increase supplier concentration and reduce the availability of substitutes, thus increasing supplier 
power.    
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 3.3.3 Allergy Segment Analysis 
Med-lab testing in the allergy segment is designed to aid in the diagnosis of, and prediction of 
severity of reactions to allergens that are either inhaled, ingested or come into contact with the 
skin.  
3.3.3.1 The Threat of Substitutes (low and increasing) 
Price : Performance 
The Allergy segment of med-lab testing has two significant, yet very different, substitute threats: 
physician delivered tests (Skin prick testing (SPT) and Oral Challenge) and point of care 
technology (POCT). The two physician delivered tests are currently in common use, and thus 
offer a medium level substitute threat to med-lab. As previously described, POCT refers to a 
technology and a related group of products currently under development, that would modify the 
mode of test delivery for a subset of the tests (screening) currently provided by med-lab testing 
and physician testing. Genomics is not considered to be a relevant substitute threat for med-lab 
screening for allergy, as the timeline required to achieve genomic allergy screening capability is 
likely to be well beyond the 5-10 year planning horizon of this paper.  
 
Two examples of the large scale conventional instruments currently used by med-lab service 
providers are the Phadia ImmunoCap 250 and Euroimmun Analyser 1. Both analysers use 
Enzyme-Linked Immunosorbent Assay (ELISA) test methods and are relatively large units, suited 
to large, centralized laboratories. These platforms offer high sensitivity screening assays (tests) 
and in Phadia’s case also offer secondary, high-specificity allergy components testing.   
 
Phadia also has a point of care technology (POCT) product under development that has the ability 
to screen for allergens using a minute sample of whole blood that can be easily collected with a 
finger prick. Although this test will be less sensitive than those of full sized equipment in the 
laboratory, it has very low impact on the patient and offers almost instantaneous results, making it 
very compelling for physicians and patients alike. It is therefore likely that most allergen screen 
tests will move to POCT, with only higher specificity (confirmation type) tests remaining on the 
large scale laboratory test instruments that are currently used by the med-lab service providers.  
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 Skin prick testing (SPT) involves the allergy specialist piercing the surface of the skin (forearm) 
with a lancet (type of needle) multiple times to create tests sites and then applying different 
reagents, each with a cocktail of allergens, to distinct sites to identify allergic response. No test 
instruments are required to conduct the test. Although currently subject to lower specificity than 
advanced med-lab instruments due to cross-reactivity, SPT are very familiar to allergy specialists. 
For more allergy specialists to move away from SPT to med-lab they would need to see an 
economic payback (incremental revenue from being able to see more patients due to faster visits 
is greater than the loss of SPT revenue from MSP), as well as clinical value to the patient. It is 
also likely that future generations of SPT reagents will employ more sophisticated reagents that 
address cross-reactivity, narrowing the value gap between them and component level med-lab 
tests. Since the improvement in price-to-performance associated with switching from SPT to 
med-lab is insignificant, a switch to POCT is more likely. POCT offers the allergy specialist an 
opportunity to continue to provide in-house service (and billing), speed up service delivery, and 
improve the patient experience. In such an instance the real question becomes the cost of POCT 
equipment and assays. POCT costs are currently prohibitively high but they are likely to fall 
dramatically in the future. 
  
To summarize this discussion and test conclusions drawn in the preceding section, Table 3.3.3 
(below) maps price and performance attributes against each substitute service. The table 
reinforces the prior suggestion that the best future state combination of tests, based on price-to-
performance ratio would be a POCT screen (preliminary test) to identify possible allergens, 
followed by a med-lab allergy components test to rule our cross-reactivity and predict reaction 
severity.   
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 Table 3.3.3: Price and Performance Comparison for Substitutes (Allergy Segment)  
  Substitutes Method Instrument Price Convenience Sensitivity Specificity 
Skin prick 
test 
Multiple 
reagents 
applied 
directly to 
pricked 
forearm 
n/a Free -
MSP 
(Cost 
Low) 
× Painful  
× Irritating 
• Physician 
location 
√ Immediate 
results 
• Med • Med 
Oral 
Challenge 
Allergen 
ingested 
orally under 
emergency  
medical 
supervision  
n/a Free-
MSP 
(Cost 
Low) 
× Stressful 
× Potentially 
harmful 
× Time 
consuming 
• Physician 
location 
√ High √ High 
Med Lab 
(Screen) 
IV draw or 
Finder prick 
/ stick 
Phadia 
ImmunoCap 
100/250; 
Euroimmun 
Analyser 1 
Free - 
MSP 
(Cost  
Low) 
× Painful 
× Separate 
location 
• Next day 
results 
√ High • Med 
Med Lab 
(Component)  
IV draw or 
Finder prick 
/ stick 
Phadia 
ImmunoCap 
100/250 
Paid – 
Med 
(Cost 
Med) 
× Painful 
× Separate 
location 
• Next day 
results 
√ Predicts 
reaction 
severity 
√ High  √ High  
POCT Test 
(Screen) 
Finger prick 
/ stick 
Phadia 
Abbott? 
Free – 
MSP? 
(Cost 
High) 
√ Low pain 
√ Low 
irritation 
√ Same or 
separate 
location 
√ Near-
immediate 
results 
• Med • Med 
[Source: Author] 
Summary 
 
From the above assessment, it is clear that there is currently a low threat to med-lab allergy 
testing from substitute methods such as SPT and POCT, and an increasing threat from POCT (to 
both med-lab and SPT) in the future, as the technology develops and costs drop.  
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 3.3.3.2 
3.3.3.3 
Buyer Power (medium-high and stable) 
The government can be considered to have significant bargaining power as it is very large and 
concentrated compared to med-lab service providers, purchasing more than 95% of allergy 
segment output, and has good information about public rival pricing (LifeLabs, 2011). Although 
the government could threaten further backward integration through the expansion of the public 
lab system, such a threat would not be considered to be credible as it would mean moving away 
from its core strength in acute care, and most likely result in an increase in the overall cost of 
service delivery.  
 
The price sensitivity of government is considered to be moderate. Although med-lab spending is a 
significant cost, the allergy segment makes up a very small portion of the overall health budget. 
This is also reinforced by the fact that substitutes such as POCT do not yet have good price-to-
performance ratios, nor strong reputations for quality. 
 
Overall, for the allergy segment, the buyer power of government is considered to be medium-to-
high and stable. 
Supplier Power (medium-high and stable) 
In Canada, Phadia is the largest supplier to the allergy segment, with testing for 650 allergens and 
70 allergen components (Phadia, 2011). Another significant European supplier that has a 
comprehensive 200 allergen (Euroimmun,2011) line of tests is Euroimmun, however it is yet to 
attain Health Canada approval for its line of allergy products. 
 
The very high concentration of suppliers capable of providing comprehensive test platforms for 
allergy and the relatively low percentage of total supplier output consumed by the BC med-lab 
industry, leads to high supplier bargaining power. This is moderated by the fact that suppliers are 
not significantly larger than rivals (med lab service providers) and cannot credibly threaten 
forward integration. As such supplier power in the allergy segment is medium to high. 
 
Looking into the future, supplier power is likely to stay high as allergy is a specialized, relatively 
low volume segment that is unlikely to attract more suppliers. Thus, overall supplier power in the 
allergy segment is medium to high and stable.  
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 3.3.3.4 Allergy Segment Summary 
The figure below presents the conclusion of medium industry attractiveness (average 
profitability) for the allergy segment, based on the positive elements of low rivalry and low threat 
of entry, offset by the negative elements of significant buyer power and supplier power. The 
future industry attractiveness for the segment is decreasing primarily due to an increasing threat 
of significant disruption by substitute services delivered via POCT.   
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 Figure 3.3.3: Porter’s 5 Forces Analysis of the Allergy Segment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Source: Author] 
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 3.3.4 Autoimmune Segment Analysis 
Med-lab testing in the autoimmune segment is designed to diagnose and monitor the progression 
of a variety of autoimmune diseases, including:  lupus, rhumetoid arthritis, celiac disease and 
antiphospholipid syndrome (APS).  
3.3.4.1 
3.3.4.2 
The Threat of Substitutes (very low and stable) 
The autoimmune segment of med-lab testing is not currently threatened by substitution to a 
service from another industry. Unlike the tests conducted in the allergy segment, med-lab test for 
autoimmune diseases are much more complicated and have much longer cycle time, including 
long incubation periods, thus making them far less susceptible to displacement by POCT. Med-
lab testing is also not likely to be affected by substitution for physicians by naturopaths, as med-
lab testing is a vital diagnostic aid in either instance. Finally, genomics is not considered to be a 
relevant substitute threat for med-lab screening for autoimmune disease, as the time required to 
achieve genomic autoimmune disease screening capability is likely to be beyond the 5-10 year 
planning horizon of this paper.  
 
From the above assessment, it is clear that there is currently a very low threat to med-lab 
autoimmune testing from any substitute services delivered by other industries, and no indication 
of the threat increasing in the next 5-10 years (unless unexpected advancements in genomics 
occur).  
Buyer Power (medium and stable) 
The government can be considered to have significant bargaining power as it is very large and 
concentrated compared to med-lab service providers. It purchases 100% of autoimmune segment 
output and has good information about public rival pricing. Although the government could 
threaten further backward integration, i.e. expansion of the public lab system, such a threat would 
not be considered to be credible as it would mean moving away from its core strength in acute 
care and most likely result in an increase in the overall cost of service delivery.  
 
The price sensitivity of government is considered to be low-moderate as although med-lab 
spending is a significant cost, the autoimmune segment makes up a very small portion of its 
overall health budget. This is also reinforced by the fact that no viable substitutes currently exist. 
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Overall, for the autoimmune segment, the buyer power of government is considered to be 
medium and stable.  
3.3.4.3 Supplier Power (medium-high and increasing) 
In Canada, the autoimmune segment is serviced by a number of suppliers which include 
DiaSorin, Bio-Rad Laboratories, DAS, Inova Diagnostics, Immuno Concepts, Euroimmun, and 
Phadia (the latter two also service the allergy segment). Since this segment has a complicated 
array of suppliers and products, it is important to understand product differentiation before 
commencing analysis of supplier power.  
Product Differentiation 
Antinuclear antibody (ANA) testing, which is used in the detection of lupus and mixed 
connective tissues disease, is the most instructive example of differentiation by test method. It is 
the most extensively used category of test used in the segment and provides an opportunity to 
examine supplier-technology associations as well as the associated price-to-performance issues.  
The table below provides a summary of supplier product offerings for ANA testing.  
 
Examination of Table 3.3.4 below reveals a number of important segment characteristics that 
impact supplier power including: wide variations in breadth of supplier offerings across and 
within technology categories (including open and proprietary consumables models), buyer agent 
(physician) power and preference for certain technologies, and the imperfect substitute nature of 
alternate technology offerings. Each of these characteristic will be incorporated into the supplier 
power analysis below. 
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 Table 3.3.4: Product Offerings for ANA Testing (Autoimmune segment)  
 Technology 
 
Supplier, Instrument, 
(Menu) 
Price 
(Cost) 
Convenience 
(Physician) 
Sensitiv-
ity 
Specific-
ity 
Immuno-
Fluorescence 
Assay (IFA)     
• Immuno Concepts 
AFT2000 (Broad)  / 
Image Navigator 
• Innova Quanta-
Lyser (Broad) / 
NOVA View  
• DAS IF Prep / MLB 
Bion (Broad) via 
Qualisys 
• Bio-Rad PhD / 
Open (Broad) 
• DAS AP16/22 / 
Euroimmun 
Free 
MSP 
(High 
Cost) 
× Semi-
quantitative 
and subjective 
× Complex and 
difficult for 
family 
physician to 
interpret 
√ American 
College of 
Rheumatology 
endorsed  
√ Very 
High 
• Med 
Enzyme-linked 
immunosorbent 
assay (ELISA 
/EIA) 
 
• ImmunoCAP100/25
0 (Broad) 
• Innova DSX/DS2 
(Broad) 
• Innova Quanta-
Lyser (Broad) 
• DiaSorin Liaison 
(Narrow) 
• Bio-Rad Evolvis 
(Mid) 
• Euroimmun 
Analyser 1 (Broad) 
Free 
MSP 
(Low 
Cost) 
× Prone to 
missing some 
outlier 
conditions  
√ Quantitative 
and objective  
• Med- 
High 
√ High 
MultiplexFlow 
Immunoassay  
• Bio-Rad BioPlex 
2200 (Mid) 
Free 
MSP 
(Low 
Cost) 
× Prone to 
missing outlier 
conditions  
√ Quantitative 
and objective 
√ Easy to 
interpret 
• Med-
High 
√ Very 
High  
[Source: Author] 
 
Supplier Power Analysis 
Supplier concentration is high in the autoimmune segment and the percentage of supplier output 
that the BC med-lab industry purchases is quite low, leading to high supplier bargaining power. 
This is further reinforced by a number of suppliers having closed systems, in which only 
proprietary consumables can be used, e.g. Euroimmun in IFA and BioRad in BioPlex. Although, 
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 these characteristics are somewhat moderated by the suppliers not having the competence to 
credibly threaten forward integration, bargaining power is high. Med-lab service providers are 
also quite insensitive to price because most supplier offerings are differentiated based on 
technology which has different performance characteristics, or tests menu which affects operating 
decisions, thus significantly reducing the number of viable substitute products.  
 
Switching costs in this segment are moderate to high, especially in instances where platforms can 
only run proprietary consumables (such as the Euroimmun IFA instrument which only accepts 
Euroimmun media).  
 
The above expression of high supplier power is moderated by the fact that some suppliers have 
made significant technology specific investments. For example, Bio-Rad has invested heavily in 
BioPlex technology and needs partners to reach broad based adoption, thus reducing their power. 
Bio-Rad has a lot riding in the success of its Bio-Plex platform and other EIA and IFA suppliers 
have a lot to lose. This tension between technologies increases competition between suppliers in 
the short term, reducing supplier power. Once BioPlex technology establishes itself or another 
technology prevails, supplier power will increase again.   
 
A final important consideration related to technology selection is the active role of the buyer’s 
agent (physician) in this segment. The American College of Rheumatology (ACR) is an active 
participant in the technology debate (see Appendix B). Despite other techniques offering cost 
advantages to med-lab operators and utility advantages to family physicians, the ACR has 
published a position statement that strongly endorses IFA, calling it “…the gold standard for 
ANA testing…” (ACR, 2009). Such position statements have significant influence on market 
offerings and have the potential to stall new technology offerings such as BioPlex. In the long 
run, such statements are likely to reduce technology diversity, increasing incumbent supplier 
power. 
 
Thus, overall supplier power in the autoimmune segment is medium-high and increasing. 
  
 47
 3.3.4.4 Autoimmune Segment Summary 
The figure below presents the conclusion of high industry attractiveness (above average 
profitability) for the autoimmune segment, based on the positive elements of low rivalry, low 
threat of entry, and low substitute threat, partially offset by the negative elements of significant 
supplier power, and moderate buyer power. The future industry attractiveness for the segment is 
stable as no major threats to profitability have been identified.  
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 Figure 3.3.4:  Augmented Porter’s 5 Forces Analysis of the Autoimmune Segment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Source: Author] 
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 3.3.5 Coagulation Segment Analysis 
Med-lab testing in the coagulation segment is designed to diagnose and manage treatment for 
disorders of coagulation that can lead to an increased risk of bleeding (hemorrhage) or obstructive 
clotting (thrombosis).  
3.3.5.1 The Threat of Substitutes (low-medium and increasing rapidly) 
The coagulation segment of med-lab testing has three significant, yet very different, substitute 
threats.  
 
The first is next generation pharmaceuticals, such as Edoxaban. These are still in development 
and have yet to prove claims of patient agnostic dosing. However, if they do they will disrupt the 
biggest portion of coagulation testing, PT/INR (previously defined in section 2.2.4.2), and thus 
should be considered a medium-high threat for the future.  
 
The second is genomics which is likely to be able to screen for predisposition to current 
generation stoke medications such as warfarin (Coumadin) within the planning horizon of this 
paper (5-10 years). This would reduce med-lab test volumes for chronic disease monitoring 
(PT/INR) but not eliminate them, assuming that the current generation medications are not made 
redundant by next generations medications. Also, next generation pharmaceuticals may not be 
100% government funded, driving many lower income individuals to stay with existing courses 
of therapy. Genomics thus represents a low-medium threat for the future.  
 
Lastly there is POCT. As previously discussed, POCT refers to a technology and a related group 
of products, some of which are currently available, such as the Abbott i-STAT system, and some 
of which under development, that would modify the mode of test delivery for a major subset of 
the tests currently provided by med-lab testing. POCT represents a low-medium threat now, as it 
is already being used in an increasing number of acute care facilities to test PT/INR, and a high 
threat in the future. 
 
Abbott has a point of care technology (POCT) product (I-STAT) that has the ability to test for PT 
/ INR using a minute sample of whole blood which can be easily collected with a finger prick 
(Abbott, 2011). Although this test will be less sensitive than those of full sized equipment in the 
laboratory, it has very low impact on the patient and offers almost instantaneous results. This 
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 makes it very compelling for physicians and patients alike. It is therefore possible to envisage a 
likely future where all chronic disease management related coagulation testing moves to POCT in 
patients’ homes or local clinics, and all acute testing occurs in acute care clinics, with only 
marginal or complex cases being sent to the larger, higher sensitivity equipment that resides in 
large scale laboratories. If the main hematological tests such as CBC (Complete Blood Count, a 
broad based screen for disease) and PT / INR moved to POCT, it would reduce total test volumes 
in outpatient servicing laboratories by about 10% (LifeLabs, 2011) 
 
To summarize the discussion and test conclusions drawn in the preceding section, Table 3.3.5 
maps price and performance attributes against each substitute service. The table reinforces the 
suggestion that the best future state combination of tests, based on price-to-performance ratio, 
would be POCT testing for chronic disease management in patients’ homes, POCT testing for 
acute conditions in acute care clinics, and high sensitivity, high specificity testing in centralized 
laboratories for complex or marginal cases (to reduce false negative and false positive test 
results). This assumes that next generation pharmaceuticals do not render chronic coagulation 
related disease monitoring redundant.   
 
From the above assessment, it is clear that there is currently a low-to-medium threat to med-lab 
coagulation testing from substitute methods such as POCT and a substantially increasing threat 
from genomics, POCT, and next generation pharmaceuticals (to both med-lab and POCT) in the 
future, especially as the new technologies develop and costs drop.  
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Table 3.3.5: Price and Performance Comparison for Substitutes (Coagulation Segment) 
Substitutes Method Instrument Price Convenience Sensitivity Specificity 
POCT 
(chronic 
disease mgmt 
@ home or 
clinic) 
Finder 
prick / 
stick  
Abbott        
i-STAT 
Free -
MSP 
(Cost 
High) 
× May not 
detect 
marginal 
issues 
√ Low pain 
√ At home  
√ Immediate 
results 
• Med √ High 
POCT (acute 
care @acute 
care clinic or 
hospital) 
IV draw or 
Finder 
prick / 
stick  
Abbott        
i-STAT 
Free-
MSP 
(Cost 
Med) 
× Not capable 
of add-on 
testing 
√ Low pain 
√ Immediate 
results 
• Med √ High 
Med Lab  
(chronic 
disease mgmt 
& acute care)  
IV draw Beckman 
Coulter ( IL) 
ACL TOP, 
Siemens 
(Sysmex) 
CA-7000 
Free - 
MSP 
(Cost  
Low) 
× Painful and 
stressful 
× Separate 
location 
• Next day 
results 
√ High √ High 
Genomics 
(predisposition 
to therapeutic 
drugs)  
IV draw or 
Finder 
prick / 
stick 
? Paid – 
Med 
(Cost 
Med) 
× Separate 
location 
• Delayed 
results 
√ Enables less 
frequent 
monitoring in 
the long run 
√ High  √ High  
Pharma 
(next 
generation 
therapeutic 
drugs) 
n/a n/a Free – 
MSP? 
(Cost 
High) 
√ Avoids 
constant 
monitoring 
• May have 
adverse 
effects on 
certain 
conditions 
• May have 
adverse drug 
interactions 
• n/a • n/a 
[Source: Author] 
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 3.3.5.2 
3.3.5.3 
Buyer Power (medium–high and increasing) 
The government can be considered to have significant bargaining power as it is very large and 
concentrated compared to med-lab service providers. It purchases 100% of coagulation segment 
output and has good information about public rival pricing. Although the government could 
threaten further backward integration, i.e. expansion of the public lab system, such a threat would 
not be considered to be credible as it would mean moving away from its core strength in acute 
care, and most likely result in an increase in the overall cost of service delivery. That said, a 
backward integration into POCT services that support the increasing trend towards community -
based acute care centres (e.g. Joe Segal Outpatient Centre operated by Fraser Health Authority, 
and the Ladysmith Acute Care Centre operated by Vancouver Island Health Authority) is credible 
and likely, and increases buyer power into the future.  
 
The price sensitivity of government is considered to be moderate. Although med-lab spending is a 
significant cost, the coagulation segment makes up a small portion of its overall health budget. 
This is also reinforced by the fact that substitutes such as POCT do not yet have good price-to-
performance ratios, nor strong reputations for quality. This too is likely to change as POCT, 
genomics and next generation pharmaceuticals develop. 
 
Overall, for the coagulation segment, the buyer power of government is considered to be 
medium-to-high and increasing. 
Supplier Power (high and stable) 
The very high concentration of suppliers capable of providing comprehensive laboratory test 
solutions for coagulation and the relatively low percentage of total supplier output consumed by 
the BC med-lab industry, leads to high supplier bargaining power. This is amplified by the fact 
that suppliers (Siemens, Danaher - owners of Beckman Coulter) are significantly larger than med-
lab service providers. Although suppliers have extensive financial resources, threats to forward 
integrate would not be considered credible. They would result in the suppliers deviating from 
their core competency of test and instrument R&D and commercialization. Overall, supplier 
power in the coagulation segment is high. 
Rivals in the industry are currently quite insensitive to price as few alternative products exist.  
Switching costs are moderate-high as the suppliers usually have broader involvement in the 
laboratories.   
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 Looking into the future, supplier power is likely to stay high as coagulation is a specialized, high 
volume segment that has a small number of very well established big players. Thus, overall 
supplier power in the coagulation segment is high and stable.  
3.3.5.4 Coagulation Segment Summary 
The figure below presents the conclusion of medium industry attractiveness (average 
profitability) for the coagulation segment, based on the positive elements of low rivalry, low 
threat of entry and low-to-medium threat of substitutes, offset by the negative elements of 
significant supplier power and buyer power. The future industry attractiveness for the segment is 
decreasing due to an increasing threat of major disruption by substitute services (delivered via 
POCT, genomics or pharmaceuticals).   
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 Figure 3.3.5:  Augmented Porter’s 5 Forces Analysis of the Coagulation Segment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Source: Author] 
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 3.3.6 Porter’s Forces Analysis Summary 
The following table summarizes forces and trends in each segment, thus highlighting common 
themes across, and contrasts between, segments.  
 
Table 3.3.6: Porter’s 5 Forces Analysis by Industry Segment 
 Segment Strongest Forces Current 
Attractiveness 
Change Drivers Future State 
Allergy • Supplier Power 
• Buyer Power 
• Medium 
(average 
profitability) 
× POCT 
× Specialist  
administered 
tests 
× Low-medium 
(below-average 
profitability) 
 
Autoimmune • Supplier Power √ High       
(above-average 
profitability) 
• Instrument  
technology  
√ High       
(above-average 
profitability) 
 
Coagulation • Supplier Power 
• Buyer Power 
• Medium  
(average 
profitability) 
× POCT 
× Next Gen Drugs 
× Genomics 
× Low        
(below-average 
profitability) 
 
Based on the summary above, supplier power is the most prominent and common current and 
future threat to med-lab appropriation of value, closely followed by buyer power. Substitutes, 
enabled by new technologies, are the most significant threat to the future creation of value by the 
med-lab industry.  
 
3.4 Political Landscape Analysis 
 
Since the health budget makes up approximately 35% of the total provincial budget, the 
government will continue to be very interested in containing costs and getting the best possible 
value for money out of the health system (Province of British Columbia, 2011). For the med-lab, 
the most direct method of cost control is via the pricing and volume controls previously 
discussed. However, other government initiated cost reduction activities are under way and more 
are likely. 
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 An important example of an active government initiated cost reduction program is the Lower 
Mainland Laboratory Consolidation Project which is aimed at consolidating public med-lab 
testing in the lower mainland (Ministry of Health Services, 2009). Greater public med-lab system 
integration would improve efficiency through back-office consolidation and the retirement of 
excess med-lab capacity. Excess capacity exists in the industry directly as result of the time 
critical and life and death nature of the services provided, especially in hospital settings which 
require significant excess capacity to deal with peaks in demand. Thus, excess capacity can never 
be eliminated but it can be reduced by consolidating med-lab facilities and blending urgent 
inpatient work with less urgent outpatient work.  
 
A strong provincial government push for greater system integration is currently unlikely due to 
the current political instability in the incumbent and opposition parties. However, it remains a 
strong possibility for the future. In the mean time, the Lower Mainland lab consolidation project 
is likely to proceed at a slow pace, delivering mainly back-office consolidation savings. It is not 
likely to deliver any significant retirement of capacity as the centralized, large scale, laboratories 
and collection networks that would be required do not currently exist within the public system. 
Private involvement or integration with the public would deliver some of the missing scale and 
collection network benefits so the government is likely to consider it. However, once again, it 
would take political courage that is currently lacking in provincial leaders due to recent leadership 
instability and the potential for announcement of an early provincial election. In the long run both 
the NDP and the Liberal party are likely to consider broader private involvement. However, it is 
far less likely to move forward under the NDP as they would run the risk of disenfranchising 
some of their key constituents – the unions.       
 
The above described government efforts to contain cost are most likely to have no net impact on 
future profitability of the med-lab industry in BC as they will likely be achieved through 
initiatives to improve efficiency and effectiveness.     
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 4: Conclusions and Recommendations 
 
4.1 Industry Level Summary 
 
The preceding analysis revealed that medical diagnostic laboratory testing industry in British 
Columbia is a mature industry and currently has a medium-to-high level of attractiveness (above 
average profits), primarily as a result of low rivalry and low threats to entry.  
 
Looking into the future, the value created by the health system is likely to grow because of 
incremental advancements in the utility of med-lab services and improvements in the quality of 
physicians’ decision making, enabled by integrated data (EMR). However, the value created by 
med-lab incumbents is likely to decrease because of a stable or reduced willingness-to-pay by the 
government, and an increase in input costs.  
      
Despite the predicted downward pressure on incumbent profitability, opportunities to capitalize 
on changes and create new value exist. The most immediate opportunity in a number of segments 
is for incumbents to diversify into POCT-enabled substitutes. Willingness-to-pay for POCT 
delivered tests for chronic disease management is likely to be high. Incumbents could provide 
POCT services under MSP or charge consumers for a premium mode of service delivery (private 
providers only), even if the government does not support funding POCT above the current, 
conventional med-lab level.   
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 4.2 Allergy Segment  
4.2.1 Conclusion 
The analysis in Chapter 3 revealed that the allergy segment is in a growth phase and currently has 
medium industry attractiveness (average profitability), based on the positive elements of low 
rivalry and low threat of entry, offset by the negative elements of significant buyer power and 
supplier power.  
 
The future industry attractiveness for the segment is decreasing primarily due to an increasing 
threat of significant disruption by substitute services delivered via POCT. POCT threatens to 
make current core med-lab assets – large allergy test platforms – redundant by enabling buyer 
agents (allergy specialists) to deliver quick and convenient services directly to the patient, thus 
eliminating med-labs from most consultations.  
 
Environmental factors are resulting in a trend increase in the prevalence of allergy, increasing the 
growth of demand for testing in the segment. The segment is expected to grow at an annual rate 
of 10% in the near future If the med-lab industry does not diversify into POCT service delivery, 
most of this additional demand is likely to be captured by buyer agents (physicians).  
4.2.2 Recommendation 
The key to maintaining the medium level of attractiveness of allergy segment in the future is for 
med-lab incumbents to take advantage of their superior capabilities and know-how in managing 
licensing and accreditation, operating instrumentation, and accessing capital. The 
recommendation below takes advantage of these capabilities. 
 
It is recommended that med-lab providers collaborate with allergy specialists to install POCT 
allergen testing capability at locations close to the specialists’ place of practice. This would be of 
value to patients as it would give them nearly instant results that they could quickly take, virtually 
or physically, to the allergy specialist. It would be of value to the allergy specialist because they 
would be able to dedicate the time they would normally spend on skin prick testing (SPT) to 
seeing more patients. They would avoid purchasing and running an instrument, including 
specialized staffing, and they would avoid the complexity and cost of achieving DAP 
accreditation and managing instrument quality control (QC) and maintenance. The co-location of 
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 POCT and med-lab collection would also make collection of additional specimens for 
confirmations or components testing very convenient for the patient and physician. 
 
It is also recommended that med-lab providers engage POCT suppliers, such as Phadia and 
Abbott, capable (now or in the near future) of servicing the allergy segment to identify equipment 
that would best service patient and physician needs. Med-lab providers should continue to 
procure higher capacity centralized instruments, such as the Phadia ImmmunoCap 250. However, 
specifications should complement rather than duplicate POCT. Since suppliers to the segment are 
highly concentrated, med-lab service providers are advised to maintain active relationships with 
two parties. 
 
4.3  Autoimmune Segment  
4.3.1 Conclusion 
The analysis in Chapter 3 revealed that the autoimmune segment is in the mature phase and 
currently has high industry attractiveness (above average profitability), based on the positive 
elements of low rivalry, low threat of entry, and low substitute threat, partially offset by the 
negative elements of significant supplier power, and moderate buyer power.  
 
The future industry attractiveness for the segment is stable, as no major threats to profitability 
were identified. One moderate threat to future economic profits of the industry could come from 
further concentration of the already concentrated supplier base. Key actors in this instance are the 
buyers’ agents (American College of Rheumatology, BCMA). They have the ability to reduce 
input options by endorsing a very limited subset of available technologies, as has been the case 
with IFA. If such endorsements continue in the long run (50% probability), they are likely to 
reduce technology diversity and thus increase incumbent supplier power. 
 
In addition, population demographics, a fundamental demand driver for the segment, are 
favourable. A growing and aging population will require more autoimmune disease testing and 
management to maintain or improve quality of life. The segment is expected to grow at an annual 
rate of 3-5%. 
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 4.3.2 Recommendation 
The key to maintaining the high level of attractiveness of autoimmune segment in the future is for 
med-lab incumbents to take advantage of their extensive in-house know-how and experience with 
alternative technologies.  
 
It is recommended that med-lab providers educate family physicians and rheumatology specialists 
regarding the benefits and best uses of complementary test methods (such as IFA and Bio-Plex), 
as well as how to interpret results from those methods. By educating and influencing physicians 
regarding the complementary value of different technologies, med-lab providers could mitigate 
the threat of continued single-test technology endorsements. Initially, med-lab providers could 
explain the value of using new, highly specific BioPlex technology to rapidly screen for the most 
clinically significant antigens and allow conventional, highly sensitive IFA technology to 
examine outlier conditions and confirm diagnosis.  
 
It is also recommended that med-lab providers continue to work with IFA providers while they 
begin to engage BioPlex technology as a complement, with the aim of running both in parallel 
until one technology prevails or their complementary nature is validated in practice. The latter 
state is most likely and clearly preferable from the supplier power mitigation perspective.  
 
4.4 Coagulation Segment 
4.4.1 Conclusion 
The analysis in Chapter 3 revealed that the coagulation segment is in the mature phase and 
currently has a medium level of attractiveness (average profitability), based on the positive 
elements of low rivalry, low threat of entry and low threat of substitutes, offset by the negative 
elements of significant supplier power and buyer power.  
 
The future industry attractiveness for the segment is decreasing due to an increasing threat of 
major disruption by substitute services delivered via pharmaceuticals, genomics or POCT.  
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 Next generation pharmaceuticals, such as Edoxaban, are still in development and have yet to 
prove claims of patient agnostic dosing. However, if they do they will disrupt the biggest portion 
of coagulation testing, PT/INR, and thus should be considered a medium-high threat for the 
future.  
 
Genomics is likely to be able to screen for predisposition to current generation stroke medications 
such as warfarin (Coumadin) within the planning horizon of this paper (5-10 years). This would 
reduce med-lab test volumes for chronic disease monitoring (PT/INR) but not eliminate them, 
assuming that the current generation medications are not made redundant by next generation 
medications. Also, next generation pharmaceuticals may not be 100% government funded, 
driving many lower income individuals to stay with existing courses of therapy. Genomics thus 
represents a low-medium threat for the future.  
 
POCT threatens to make current core med-lab assets – large coagulation test platforms –
redundant by enabling substitute service providers to deliver quick and convenient services 
directly to the patient (at their home, long term care facility or local or mobile clinic), thus 
eliminating med-labs from most therapeutic drug monitoring tests, including PT/INR. POCT 
represents a low-medium threat now, as it is already being used in an increasing number of acute 
care facilities to test PT/INR, but a high threat in the future. 
 
However, population demographics are favourable. A growing and aging population will require 
more chronic heart and stroke disease monitoring (PT/INR) and other med-lab coagulation 
services. The segment is expected to grow at an annual rate of 3-5%. 
4.4.2 Recommendation 
The key to improving the medium level of attractiveness of coagulation segment in the future is 
for med-lab incumbents to take advantage of their superior capabilities and know-how in 
managing licensing and accreditation, operating instrumentation, and accessing capital. The 
recommendation below takes advantage of these capabilities. Although this approach is very 
similar in principle to that employed in the allergy segment, the circumstances in the coagulation 
segment are very different. 
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 It is recommended that med-lab providers collaborate with regional health authorities to install 
POCT coagulation (PT / INR) testing capability at locations close to or within community acute 
care clinics, as well as at nominated patient service centres, and throughout the long term care 
facility network that they service. This would be of value to patients as it would give them near ly 
instant results that they could quickly take, virtually or physically, to their family physician or 
specialist to identify an appropriate adjustment to their level of medication. It would be of value 
to the family physician as they would be able to dedicate the time they would normally spend 
consulting in person to seeing more patients, and they would avoid purchasing and running an 
instrument themselves, including specialized staffing. Physicians would also avoid the 
complexity and cost of achieving DAP accreditation and managing instrument quality control and 
maintenance. Much like for the allergy segment, the co-location of POCT and med-lab collection 
would also make collection of additional specimens for confirmations or additional testing very 
convenient for the patient and physician. 
 
It is also recommended that med-lab providers engage POCT suppliers, such as Abbott, who are 
capable of servicing the coagulation segment to identify equipment that would best service 
patient and physician needs. Med-lab providers should continue to procure higher capacity 
centralized instruments, such as the Sysmex CA-7000. However, specifications should 
complement rather than duplicate POCT. Since suppliers to the segment are highly concentrated, 
med-lab service providers are advised to maintain active relationships with two parties. 
 
It is further recommended that med-lab providers exploit opportunities to engage in activities that 
are adjacent to theirs, even if they use different technologies. Much like the application of 
molecular diagnostics in microbiology, it is recommended that med-lab providers build 
capabilities in genomic screening for warfarin predisposition and the like.  
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 5: Further Analysis 
 
Although it was the clients’ explicit request to not tackle internal analysis as part of this study, it 
is recommended that a follow-up internal analysis of LifeLabs’ resources, capabilities and 
strategies, and a subsequent scenario analysis of different possible future industry environments 
be conducted to assure that the unique competitive advantages of the client firm are considered as 
part of the strategy formulation process. An internal analysis will identify the sources of 
sustainable competitive advantage that the client possesses, and thus enable the evaluation of how 
those strengths should be applied to mitigate the threats that were discussed in the preceding 
external analysis  
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 6: Appendices  
6.1 Appendix A  
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 6.2 Appendix B 
American College of Rheumatology 
 
POSITION STATEMENT 
 
 
SUBJECT:    Methodology of Testing for Antinuclear Antibodies 
 
PRESENTED BY:   American College of Rheumatology 
 
FOR DISTRIBUTION TO:  Members of the American College of Rheumatology 
    Medical Societies 
    Managed Care Organizations and Third Party Carriers 
    Laboratories 
 
SUMMARY: 
 
The immunofluorescence antinuclear antibody (ANA) assay is the gold standard for ANA testing with 
greater sensitivity than solid phase assays. 
 
HEp-2 cells have approximately 100 to 150 possible autoantigens. These cells are used to detect ANAs by 
the immunofluorescence (IF) method, in which both pattern and titer can be described, and to display a 
variety of autoantigens not present in multiplex ANA tests. 
 
Many commercial laboratories and some hospital laboratories have switched their ANA screening test to 
solid phase immunoassays, such as a multiplex platform. The latter technique can screen and process large 
volumes of clinical specimens more quickly and at less cost than the traditional immunofluorescence ANA 
test using fixed HEp-2 cells as substrate. 
 
These multiplex assays can detect only the specific autoantibodies directed against the limited number 
(typically 8-10) autoantigens that are displayed. 
 
Laboratories should indicate the method used when reporting ANA results. 
 
BACKGROUND: 
 
The methodology of the tests for the detection of antinuclear antibodies has changed over the years from 
the LE cell prep, to immunofluorescence utilizing sections of various rodent organs (e.g. rat or mouse liver 
or kidney, etc.) to cell lines, in particular HEp-2. HEp-2 cells contain approximately 100 to 150 
autoantigens. These cells are used to detect ANA by the immunofluorescence method, in which both 
pattern and titer can be described, and to display a variety of autoantigens not present in the multiplex ANA 
tests. 
Researchers have seen the evolution of methodology of test for the detection of particular ANAs 
hemagglutination, to various solid phase immunoassays. 
 
Over the years, numerous investigators and commercial organizations have attempted to develop solid 
phase immunoassays for the detection of ANA and specific ANAs, which are easier and cheaper to perform 
of the literature by the committee indicates that up to 35% of patients with SLE and a positive ANA by 
immunofluorescence (IF) were negative on solid phase assays (1-4, 6-21, 23). Many commercial 
laboratories and some hospital laboratories have switched their antinuclear antibody (ANA) screening test 
to solid phase immunoassays, such as a multiplex platform, for the reasons noted above, and since the latter 
technique can screen and process large volumes of clinical specimens than the traditional 
immunofluorescence ANA test using fixed HEp-2 cells as substrate. 
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 Various national and international organizations have also been involved in the standardization of these 
tests for the harmonization of laboratory results. These include World Health Organization Centers for 
Disease Control, Dutch Red Cross and the International Union of Immunological Societies (5). 
Any laboratory test, to be most useful, must maximally distinguish patients with a particular disorder from 
related disorders. It is understood that both commercial and hospital laboratories are interested and 
committed to providing the nest laboratory tests for the diagnosis of rheumatic diseases. 
 
The immunofluorescence ANA test is the gold standard for ANA testing. When performed with a history 
and physical, it identifies almost all patient with systemic lupus erythematosus (sensitivity over 95%)(22), 
although the specificity of this assay is only 57% for SLE when compared to patients with related 
rheumatic and autoimmune disorders(22). In addition, the IF ANA is an important test for the screening 
and diagnosis of systemic sclerosis (sensitivity 85%), polymyositis and dermatomyositis (sensitivity 61%) 
primary Sjogren’s syndrome (sensitivity 48%), juvenile idiopathic arthritis (sensitivity 57%), drug-induced 
lupus (sensitivity 100%), mixed connective tissue disease (sensitivity 100%), and autoimmune hepatitis as 
well as being important in monitoring and assessing prognosis in individuals with Raynaud’s phenomenon. 
 
 
RECOMMENDATIONS: 
 
The immunofluorescence (IF) ANA test should remain the gold standard for ANA testing. 
 
Hospital and commercial laboratories using bead-based multiplex platforms or other solid phase assays for 
detecting ANAs must provide data to ordering physicians on request that their assay has the same or 
improved sensitivity and specificity compared to the IF ANA. 
 
In-house assyas for detecting ANA as well as anti-DNA, anti-Sm, anti-RNP, anti-Ro/SS-A, antiLa/SS-B, 
etc. should be standardized according to national (e.g., CDC) or international (e.g.WHO, IUIS) standards. 
 
Laboratories should specify the methods utilized for detecting ANAs when reporting their results. 
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